A *Vago*-like gene enhances dengue and Zika virus dissemination in *Aedes aegypti*

Elodie Couderc[1,2], Anna B. Crist[1], Josquin Daron[1], Hugo Varet[3], Femke A. H. van Hout[4], Pascal Miesen[4], Umberto Palatini[1,5], Stéphanie Dabo[1], Thomas Vial[1], Louis Lambrechts[1,‡,*], Sarah H. Merkling[1,‡,*]

[1]Institut Pasteur, Université Paris Cité, CNRS UMR2000, Insect-Virus Interactions Unit, 75015 Paris, France

[2]Sorbonne Université, Collège Doctoral, 75005 Paris, France

[3]Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, 75015 Paris, France

[4]Department of Medical Microbiology, Radboud University Medical Center, P.O. box 9101 6500 HB Nijmegen, The Netherlands

[5]Laboratory of Neurogenetics and Behavior, The Rockefeller University, New York, NY 10065, USA

[‡]These authors contributed equally

*Correspondence to: Louis Lambrechts (louis.lambrechts@pasteur.fr) and Sarah Merkling (sarah.merkling@pasteur.fr)

ABSTRACT

Arthropod-borne viruses (arboviruses) such as dengue virus (DENV) and Zika virus (ZIKV) pose a significant threat to global health. Novel approaches to control the spread of arboviruses focus on harnessing the antiviral immune system of their primary vector, the *Aedes aegypti* mosquito. In arthropods, genes of the *Vago* family are often presented as analogs of mammalian cytokines with potential antiviral functions, but the role of *Vago* genes upon virus infection in *Ae. aegypti* is largely unknown. We conducted a phylogenetic analysis of the *Vago* gene family in Diptera, which led us to focus on a *Vago*-like gene that we named *VLG-1*. Using CRISPR/Cas9-mediated gene editing, we generated a *VLG-1* mutant line of *Ae. aegypti* that revealed a proviral effect of this gene upon DENV and ZIKV infection. In the absence of *VLG-1*, virus dissemination throughout the mosquito's body was impaired, albeit not altering virus transmission rates. A tissue-specific transcriptome analysis revealed that the loss of *VLG-1* impacted numerous biological processes potentially linked to viral replication, such as the oxidative stress response. Our results challenge the conventional understanding of *Vago*-like genes as antiviral factors and underscores the need for further research to elucidate the molecular mechanisms underlying mosquito-arbovirus interactions.

INTRODUCTION

Arthropod-borne viruses (arboviruses) pose a significant threat to global health, causing numerous human diseases with substantial morbidity and mortality. Among the most medically significant arboviruses are the mosquito-borne flaviviruses [1]. For instance, dengue virus (DENV) infects approximately 400 million people each year and is responsible for about 100 million symptomatic cases [2-4]. In addition, Zika virus (ZIKV) emerged in more than 87 countries and territories in the last 15 years, causing severe neuropathologies and birth defects [5]. DENV and ZIKV are primarily transmitted by *Aedes aegypti* (*Ae. aegypti*), a mosquito species found throughout the tropics and subtropics whose range is expected to further expand with global change [6, 7]. To date, there are no globally approved vaccines or specific antivirals for these diseases. Traditional vector control methods are limited in efficacy because of the emergence of insecticide-resistant mosquitoes. Thus, the release of lab-modified mosquitoes that are incapable of transmitting viruses is an alternative strategy for reducing the incidence of human arboviral diseases [8, 9]. The development of such novel interventions is conditioned by the identification of optimal target genes that mediate interactions between mosquitoes and viruses [9, 10].

Female mosquitoes acquire arboviruses by biting and blood feeding on viremic vertebrate hosts. The bloodmeal is digested in the midgut, where viral particles infect epithelial cells [11, 12]. The virus then disseminates through the mosquito body, likely via circulating immune cells called hemocytes [13-15], until it reaches the salivary glands, where it replicates before being released in the saliva [16]. The mosquito can then transmit the virus to the next host during a subsequent blood-feeding event [13]. Within mosquitoes, virus infection and dissemination are hindered by physical tissue barriers [13] and innate immune pathways, including RNA interference (RNAi) [17-19], Janus kinase/signal transducers and activators of transcription (JAK-STAT), Toll, and immune deficiency (IMD) pathways, which are activated upon viral detection and trigger the production of effector molecules that can inhibit viral replication [20-22]. Most of our knowledge about antiviral immunity in mosquitoes is derived from pioneering work in the model organism *Drosophila melanogaster*. However, fruit flies are neither arbovirus vectors, nor hematophagous insects, leaving our understanding of mosquito antiviral responses incomplete [10, 20, 23].

For instance, only a few studies have investigated the role of immunoregulatory genes with cytokine-like functions, such as *Vago* genes, in mosquito immunity. The first *Vago* gene was identified in *D. melanogaster* [24] and encodes a secreted antiviral protein induced upon infection by *Drosophila* C virus (DCV) [25]. In *D. melanogaster*, *Vago* induction in response to

DCV infection requires the RNAi gene *Dicer2* [25]. In mosquitoes, a *Vago* gene called *CxVago,* was shown to limit viral replication in *Culex* mosquitoes infected with the flavivirus West Nile virus (WNV) [26]. In addition, WNV infection was found to induce the expression of *CxVago* in a *Dicer2*-dependent manner in a *Culex*-derived cell line, leading to secretion of the protein and activation of the JAK-STAT pathway via an unknown non-canonical receptor [26]. *Rel2* and *TRAF* genes were also involved in *CxVago* induction, suggesting a link between *CxVago* induction and NF-κB pathways [27]. However, the antiviral function of *Vago* genes in *Culex* mosquitoes was not investigated *in vivo*. Finally, another study using an *Aedes*-derived cell line reported an antiviral role for a *Vago* gene called *AaeVago1*, in the context of DENV and *Wolbachia* co-infection [28].

The Vago protein family is often referred to as "arthropod cytokines" because they are functionally analogous to mammalian cytokines [26, 29-31]. In dipteran insects (flies and mosquitoes), Vago proteins consist of 100-200 amino acids with a secretion signal peptide and a single domain von Willebrand factor type C (SVWC) functional domain. SVWC proteins, characterized by a repetitive pattern of eight cysteines, represent a broadly conserved protein family in arthropods, associated with responses to environmental challenges, including nutritional stress and microbial infections [29]. Despite their characteristic structural features, the functions of Vago proteins in insects remain elusive, particularly *in vivo*.

Here, we investigated the role of *Vago* genes in *Ae. aegypti* mosquitoes *in vivo* in the context of flavivirus infection. We generated and characterized a mosquito mutant line for the gene that had hitherto been called *AaeVago1* and determined its impact on infection, systemic dissemination, and transmission of DENV and ZIKV. Unexpectedly, we found a proviral effect of this gene, challenging the hypothesis that genes belonging to the *Vago* family exert exclusively antiviral functions in arthropods.

RESULTS

***VLG-1* is a *Vago*-like gene exclusively found in the Culicinae**

To investigate the role of *Vago* genes in *Ae. aegypti*, we first reconstituted their evolutionary history (Figure 1A). We identified the homologs of *AAEL000200* and *AAEL000165*, two genes that were previously described as *AaeVago1* and *AaeVago2*, in a panel of Diptera species from the Culicidae family (mosquitoes) and from the *Drosophila* genus, and we determined their phylogenetic relationships at the protein level (Supplementary Figure S1). First, we discovered that the first *Vago* gene characterized in *Drosophila melanogaster* (*DmVago*, *CG2081*) [25] is not the most likely homolog of *AAEL000200* and *AAEL000165.* These two *Ae. aegypti* genes encode proteins that are ~40-50 amino acid shorter and only share 27% and

24% identity with DmVago, respectively (Figure 1B). Reciprocally, *DmVago* does not have a homolog in the Culicidae sharing at least 30% protein sequence identity. We found that the most likely homolog of *AAEL000200* and *AAEL000165* in the *D. melanogaster* genome is an uncharacterized gene (*CG14132*), which we named "*D. melanogaster Vago-like gene*" (*DmVLG*). *DmVLG* shares 36% and 31% protein identity with *AAEL000200* and *AAEL000165*, respectively (Figure 1B). Thus, we renamed *AAEL000200* "*Ae. aegypti Vago-like gene 1"* (*AaeVLG-1*, referred to later in this study as *VLG-1*) and *AAEL000165* "*Ae. aegypti Vago-like gene 2"* (*AaeVLG-2*, referred to later in this study as *VLG-2*). A summary of our proposed updated designation of *Vago* and *Vago*-like genes is provided in Supplementary Table 1.

The overall topology of the phylogenetic tree of *Vago*-like gene homologs revealed two distinct sister clades among the Culicidae (Supplementary Figure S1). One clade encompasses members of both the Culicinae and Anophelinae subfamilies, including *AaeVLG-2*. The other clade exclusively consists of Culicinae members, including *AaeVLG-1*. The *VLG* clade that includes *AaeVLG-2* likely represents the orthologous group of *DmVLG*, whereas the clade that includes *AaeVLG-1* likely corresponds to *Vago*-like paralogs that arose by duplication of the ancestral *VLG*. This scenario is further supported by the nested and inverted position of the *AaeVLG-1* locus within an intron of *AaeVLG-2*. Our analysis suggests that the duplication occurred prior to the divergence of Anophelinae and Culicinae and was followed by a loss of the duplicated copy in Anophelinae prior to their diversification (Figure 1A and Supplementary Figure S1). Together, our analysis identified *AaeVLG-2* (previously named *AaeVago2* [28]) as the direct ortholog of *DmVLG* in *Ae. aegypti*, and *AaeVLG-1* (previously named *AaeVago1* [28]) as the duplicated copy. Accordingly, we also propose to rename the *Culex quinquefasciatus* gene *CQUJHB003889*, previously known as *CxVago* [26, 27], as *CxVLG-1* because it belongs to the *VLG-1* clade (Supplementary Figure S1 and Supplementary Table 1).

To determine whether the two *Vago*-like copies in the Culicidae family evolved under a different selection regime after the duplication event, we estimated the evolutionary rates of *AaeVLG-1* and *AaeVLG-2*. We computed the ratio of non-synonymous to synonymous substitutions (ω) for all *VLG* homologs of our panel of Culicidae and *Drosophila* species. The ω ratio, also known as dN/dS, indicates the mode and strength of natural selection, where ω=0 means that the gene is under purifying selection, ω=1 indicates neutral selection, and ω>1 indicates diversifying selection. We used a branch model that evaluates the variation of ω within the tree and tests for differences in selection regimes between lineages. According to this model, both *VLG-1* and Culicinae *VLG* are under purifying selection (ω=0.18 and ω=0.15 respectively), but slightly weaker purifying selection than Anophelinae *VLG* (ω=0.1) and *Drosophila VLG*

146 (ω=0.09) (Supplementary Figure S1 and Supplementary Table 3). This analysis suggests that
147 the *VLG* duplication in the Culicinae was followed by relaxed selective pressure on both copies.
148
149 At the amino-acid level, *AaeVLG-1* shares 57% identity with *CxVLG-1*, whereas *AaeVLG-2*
150 shares 38% identity with *CxVLG-1* (Figure 1B). *AaeVLG-1* is transcribed into a 451-bp mRNA
151 transcript encoding a protein of 113 amino acids, including a signal peptide, theoretically
152 responsible for addressing the protein to the membrane prior to its secretion, and an SVWC
153 domain with the characteristic eight-cysteine repeat (Figure 1B-D).
154
155 ***VLG-1* is persistently induced by bloodmeal ingestion in *Ae. aegypti***
156 In arthropods, *Vago* genes have been described as factors induced by biotic or abiotic stress
157 [25-29, 32-35]. To test whether *VLG-1* and *VLG-2* are induced upon viral infection in *Ae.*
158 *aegypti*, we exposed mosquitoes to a bloodmeal containing DENV serotype 1 (DENV-1) or a
159 control mock bloodmeal. We quantified the expression of *VLG-1* and *VLG-2* by quantitative
160 RT-PCR (RT-qPCR) in individual midguts, heads, and carcasses (*i.e.,* bodies without midgut
161 and head) on several timepoints post bloodmeal, from day 0 to day 9 (Figure 2). As reported
162 previously [36], we found that in *Ae. aegypti*, overall transcript abundance is ~2- to 10-fold
163 higher for *VLG-1* than for *VLG-2* across tissues (Figure 2C and 2F). A mock bloodmeal
164 triggered a persistent up-regulation of *VLG-1* transcription lasting up to 9 days post bloodmeal
165 in carcasses and heads (Figure 2B and 2C). DENV exposure triggered an additional increase
166 in *VLG-1* expression in heads on day 2 post bloodmeal (Figure 2C). No differences in *VLG-2*
167 expression kinetics were detected between the mock and the infectious bloodmeals.
168 Therefore, we chose to focus our study on the role of *AaeVLG-1* upon virus infection.
169
170 ***Ae. aegypti VLG-1*$^{\Delta}$ mutant mosquitoes do not exhibit major fitness defects**
171 To further investigate the role of *VLG-1* in *Ae. aegypti*, we generated a mutant line by
172 CRISPR/Cas9-mediated gene editing. Shortly, mosquito embryos were microinjected with
173 Cas9 coupled to 3 single-guide RNAs (sgRNAs) targeting 3 *VLG-1* exons together with a repair
174 template (Figure 3A). We isolated one generation zero (G_0) female carrying a 212-bp (55 amino
175 acids) deletion in the *VLG-1* locus, resulting from a combined 246-bp deletion and a 34-bp
176 insertion from the repair template. This G_0 female was crossed to wild-type males and G_1 males
177 carrying the deletion were crossed to wild-type females for three more generations. G_4 adults
178 carrying the *VLG-1* mutation at the homozygous state were used to establish a *VLG-1* mutant
179 line that we called *VLG-1*$^{\Delta}$. Within the same crossing scheme, we generated a control "sister"
180 line carrying the wild-type version of *VLG-1*. The *VLG-1*$^{\Delta}$ line encodes a *VLG-1* protein with
181 only 58 of the 113 original amino acids left and 81% of the SVWC functional domain truncated,
182 suggesting a *VLG-1* loss of function. We found a strong decrease of *VLG-1* transcript

183 abundance in the mutant line relative to the control line, by RT-qPCR and by RNA sequencing
184 (RNA-seq) (Supplementary Figure S2A-B), which is a hallmark of nonsense-mediated decay
185 of the aberrant mRNA [37]. We also confirmed the absence of detectable VLG-1 protein in the
186 mutant line by Western blot using a previously developed anti-VLG-1 antibody [26]
187 (Supplementary Figure S2C). No off-target effect on *AaeVLG-2* expression was detected by
188 RT-qPCR or RNA-seq in the *VLG-1*$^{\Delta}$ mutant line (Supplementary Figure S2D-E). Together,
189 these results strongly suggest that we generated a *bona fide* knock-out *VLG-1* mutant line.
190
191 To assess the impact of *VLG-1* absence on mosquito fitness, we monitored adult survival rates
192 in standard insectary conditions. Mortality rates were slightly higher in the *VLG-1*$^{\Delta}$ mutant line
193 compared to controls, particularly for males (Figure 3C-D). We also measured fecundity (*i.e.*,
194 the number of eggs laid per blood-fed female; Figure 3E) and fertility (*i.e.*, the number of viable
195 larvae hatched over total number of eggs laid; Figure 3F) and found no differences between
196 the *VLG-1*$^{\Delta}$ mutant and the control lines. In sum, *VLG-1*$^{\Delta}$ mutants are viable and display no
197 major fitness defects.
198
199 ***VLG-1* promotes systemic dissemination of DENV and ZIKV in *Ae. aegypti***
200 To investigate the role of *VLG-1* upon virus infection in *Ae. aegypti* mosquitoes, we performed
201 experimental DENV-1 or ZIKV infections and analyzed infection prevalence (proportion of
202 virus-positive tissues) and viral load (abundance of viral RNA) by RT-qPCR in individual tissues
203 (midguts, carcasses, and heads). We selected timepoints representing key steps in the
204 infection cycle: early midgut infection (day 2), systemic viral dissemination from the midgut to
205 secondary organs (day 5), and head infection (day 9) (Figure 4 and Figure 5). Midgut infection
206 prevalence is defined as the proportion of virus-positive midguts over the total number of blood-
207 fed mosquitoes. Carcass infection prevalence is the proportion of virus-positive carcasses over
208 the number of virus-positive midguts. Head infection prevalence is the number of virus-positive
209 heads over the number of virus-positive carcasses. On days 7, 10, and 14 post bloodmeal, we
210 measured viral titers in saliva samples collected from individual mosquitoes to assess virus
211 transmission levels. Transmission efficiency was calculated as the proportion of virus-exposed
212 mosquitoes with virus-positive saliva.
213
214 Upon DENV-1 infection, we found that virus dissemination was reduced in *VLG-1*$^{\Delta}$ mutant
215 mosquitoes (Figure 4). In a first experimental replicate, we found that infection prevalence in
216 the midgut (day 2), carcass (day 5) and head (day 9) was lower in *VLG-1*$^{\Delta}$ mutant mosquitoes
217 (Figure 4A-C). We also detected decreased viral loads in the *VLG-1*$^{\Delta}$ mutant midguts on day
218 5, and in heads on days 5 and 9 in the second experimental replicate (Figure 4D-F). Small
219 phenotypic differences between replicates presumably reflect minor uncontrolled variation in

220 the bloodmeal titers that result in slightly different infection dynamics. Finally, we found no
221 difference in DENV transmission efficiency between wild-type and *VLG-1*$^{\Delta}$ mutant mosquitoes
222 (Figure 4G).
223
224 Next, we performed a similar set of experiments with ZIKV and confirmed *VLG-1*'s proviral role
225 in virus dissemination (Figure 5). Two days after the bloodmeal, we found a strong decrease
226 in infection prevalence in the carcass, where only 12% of the *VLG-1*$^{\Delta}$ mosquitoes harbored
227 ZIKV RNA compared to 70% of the control mosquitoes (Figure 5A-C). In midguts, we
228 consistently found a decrease in viral loads (~10-fold) in *VLG-1*$^{\Delta}$ mutants at all three timepoints
229 (Figure 5D). In carcasses and heads, viral loads were 5- to 10-fold lower in *VLG-1*$^{\Delta}$ mutants 9
230 days post bloodmeal (Figure 5E-F). Similar to DENV, we found no detectable difference in
231 virus transmission efficiency between wild-type and *VLG-1*$^{\Delta}$ mutant mosquitoes (Figure 5G).
232
233 Of note, we estimated virus transmission efficiency with standard salivation assays that
234 potentially underestimate vector competence compared to live-host transmission assays [38],
235 which might have limited our ability to detect differences in transmission efficiency between
236 the *VLG-1*$^{\Delta}$ mutant and control lines. Together, these results reveal a proviral activity of *VLG-1*
237 upon flavivirus infection in *Ae. aegypti*. Our data demonstrate that *VLG-1* promotes flavivirus
238 dissemination across the mosquito's body but does not seem to significantly impact virus
239 transmission.
240
241 ***VLG-1* and *VLG-2* have non-additive proviral effects on DENV in *Ae. aegypti***
242 The finding of *VLG-1*'s proviral effect prompted us to test whether its paralog *VLG-2* could
243 share similar properties in *Ae. aegypti*. Using RNAi-mediated knockdown, we depleted *VLG-2*
244 transcripts in adult *VLG-1*$^{\Delta}$ mutants or control mosquitoes. Two days after injection of double-
245 stranded RNA (dsRNA) targeting *VLG-2* or *Luciferase* (as a control), mosquitoes were exposed
246 to a DENV-1 infectious bloodmeal and their heads collected 7 days later. Consistent to previous
247 results, we found that infection prevalence in heads was lower for *VLG-1*$^{\Delta}$ mutants than for wild
248 types upon control dsRNA injection (Supplementary Figure S3A). Head infection prevalence
249 was also lower in wild-type mosquitoes depleted in *VLG-2* transcripts, revealing a proviral role
250 for *VLG-2*. Finally, head infection prevalence was not further reduced in mosquitoes that were
251 depleted for both *VLG-1* and *VLG-2* transcripts (Supplementary Figure S3A). Additionally, we
252 did not detect differences in viral loads between any of the experimental treatments
253 (Supplementary Figure S2B). On the day of the bloodmeal, we tested *VLG-2* gene knockdown
254 efficiency and found a strong reduction in transcript abundance for both isoforms (*VLG-2-RA*
255 and *-RB*) in all conditions (Supplementary Figure S3C-D). Together, these results indicate that
256 *VLG-1* and *VLG-2* exert non-additive proviral effects on DENV infection in *Ae. aegypti*.

257 **The transcriptional landscape of *VLG-1* mutants is broadly altered**
258 To investigate the overall impact of *VLG-1* loss and its link with virus infection in *Ae. aegypti*,
259 we analyzed the midgut and body (carcass + head) transcriptomes of *VLG-1*$^{\Delta}$ mutant and
260 control lines on days 2, 5, and 9 after a DENV-1 or mock bloodmeal. We detected transcripts
261 from a total of ~15,000 unique genes in midguts and ~16,800 unique genes in bodies,
262 representing 75% to 85% of all annotated genes depending on the samples and conditions.
263
264 In midguts, several hundreds of genes (ranging from 236 to 681) were significantly differentially
265 expressed, defined by a fold change ≥ 2 and a p-value ≤ 0.05 between *VLG-1*$^{\Delta}$ mutants and
266 controls (Figure 6A-B and Supplementary Figure S5). The highest number of differentially
267 expressed genes (DEGs) was observed on day 2 after DENV exposure, with 380 up-regulated
268 and 301 down-regulated genes. Overall, up to 4.5% of all detected genes were differently
269 expressed between *VLG-1*$^{\Delta}$ mutants and controls in midguts. In the bodies, fewer DEGs were
270 detected, but the highest number of DEGs was still detected 2 days after DENV exposure.
271 These results suggest that *VLG-1* has a wide impact on biological processes, most prominently
272 2 days after a bloodmeal and especially in the presence of DENV.
273
274 *VLG-1*-dependent changes in gene expression occurred in the midgut and the rest of the body,
275 but the overlap between DEGs in midguts and bodies was minimal (Figure 6C-D and
276 Supplementary Figure S4). Only 18 and 34 up- or down-regulated transcripts (out of 684 and
277 592) were shared between both compartments, suggesting tissue-specific functions for *VLG-*
278 *1*. Conversely, a noteworthy overlap of DEGs was detected between the mock and DENV
279 bloodmeal conditions in both compartments, suggesting that *VLG-1*-dependent gene
280 expression is only partially affected by virus infection.
281
282 To explore the biological functions of DEGs in *VLG-1*$^{\Delta}$ mutants, we examined their gene
283 ontology (GO) annotations at the level of biological processes. We found that enriched GO
284 terms in both midguts and bodies included mainly response to oxidative stress, translation
285 regulation, and molecule transport (Figure 6E). Midgut-specific DEGs were mostly associated
286 with RNA processing and broad metabolic processes, whereas most body-specific DEGs
287 belonged to protein phosphorylation, protein modification, and ion transport categories. We did
288 not specifically identify immune genes or pathways that are differentially expressed in *VLG-1*$^{\Delta}$
289 mutants. None of the genes previously reported to be involved in the activation or function of
290 *CxVLG-1* (*Rel2*, *TRAF*, *Dicer2*, and *vir-1*) [26, 27] were DEGs in our dataset. This observation
291 suggests that *Ae. aegypti VLG-1* and its *Culex* ortholog participate in different signaling
292 pathways despite their close phylogenetic relatedness. However, several DEGs were related
293 to protein phosphorylation, particularly in DENV-exposed mosquitoes. These genes include

294 several activators of immune pathways, such as *Pelle* and *Tube* in the Toll pathway, *Hop* in the
295 JAK-STAT pathway, and *Tak* in the IMD pathway. Similarly, some DEGs identified in infected
296 midguts and related to proteolysis are often associated with the Toll or IMD pathways, such as
297 *CLIP* or *DREDD* genes. Thus, we cannot exclude a link between *Ae. aegypti VLG-1* and the
298 canonical inducible immune pathways, although it would be distinct from previous observations
299 in *Culex* mosquitoes. We also found an enrichment of DEGs involved in oxidoreduction and
300 oxidative stress response across tissues, timepoints and bloodmeal types. The anti-oxidative
301 response is predominantly reduced in the bodies of the *VLG-1*$^{\Delta}$ mutants relative to the controls,
302 suggesting that *VLG-1* limits cellular oxidation, possibly contributing to its proviral effect.
303 Finally, we observed large number of enriched GO terms related to translation regulation,
304 which might explain the broad impact of *VLG-1* across diverse biological processes.

305 **DISCUSSION**

306 In this study, we identified the *Ae. aegypti* gene *AAEL000200* as a Culicinae-specific *Vago*-like
307 gene that we renamed *AaeVLG-1*. We generated a *VLG-1* mutant line of *Ae. aegypti* that
308 displayed a slight reduction in lifespan but remained fully viable and fertile. Upon DENV and
309 ZIKV infection, we found that *VLG-1* exerted a proviral role by enhancing virus dissemination,
310 but not virus transmission. Finally, we provided a tissue-specific description of the
311 transcriptomic landscape of *VLG-1*$^{\Delta}$ mutants following a mock or DENV-containing bloodmeal.
312 This newly discovered proviral effect of *VLG-1* in *Ae. aegypti* challenges the universal nature
313 of the antiviral function of *Vago*-like genes in arthropods.
314
315 Our transcriptomic analysis revealed that the loss of *VLG-1* interferes with a wide range of
316 biological pathways. Notably, canonical immune pathways were not significantly impacted by
317 *VLG-1* loss of function. Amongst the most altered processes in *VLG-1*$^{\Delta}$ mutants was the
318 response to oxidative stress. Pro-oxidative processes were up-regulated and anti-oxidative
319 processes were down-regulated in the *VLG-1*$^{\Delta}$ mutants, suggesting that *VLG-1* confers
320 protection against oxidative stress. Hijacking of oxidative stress by viruses has been reported
321 to facilitate their genome replication [39-42]. Additionally, oxidative stress can also contribute
322 to the cellular antiviral response [43-45]. Thus, modulation of the oxidative stress response by
323 *VLG-1* could contribute to its proviral effect and explain the shorter lifespan of *VLG-1*$^{\Delta}$ mutants.
324
325 The induction mechanism of *VLG-1* remains to be elucidated. In *Culex* mosquitoes, *CxVLG-1*
326 induction depends on a NF-κB Rel-binding site [27]. We ran a promoter analysis to identify
327 binding motifs of transcription factors (TF) in the promoter sequence of *VLG-1* (Supplementary
328 Figure S6 and Supplementary Table 6). Importantly, we did not identify classical immune TF

binding motifs, such as NF-κB motifs. In contrast, we identified TF binding motifs specific to signaling pathways involved in cell cycle regulation, apoptosis and redox stress response. This observation is consistent with the hypothesis that *VLG*-1's proviral activity in *Ae. aegypti* is not associated with canonical immune pathways but rather with stress response processes.

Mechanistic insights into *VLG-1*'s mode of action in *Ae. aegypti* remain to be investigated. CxVLG-1 is secreted extracellularly in *Culex*-derived cells [26], and Vago-like proteins are presumed to be secreted in several other insect species [25, 32]. The AaeVLG-1 protein sequence contains a secretion signal peptide, but experimental evidence of extracellular localization is lacking. Technical limitations such as minute protein amounts in the mosquito hemolymph, low sensitivity of detection, and lack of adequate controls prevented us from assessing the extracellular presence of VLG-1 *in vivo* by immunoblotting. Mass spectrometry analysis of the hemolymph protein content may be required to confirm VLG-1 secretion in the extracellular environment.

Our evolutionary analyses of *Vago*-like gene homologs in dipteran insects showed that both *VLG* paralogs have been retained and maintained under slightly relaxed selective pressure since the Culicinae diversification 150 million years ago. This indicates that they did not undergo pseudogenization (*i.e.*, accumulation of deleterious mutations resulting in a non-functional gene sharing high sequence identity with the ancestral form). Our knockdown experiments also revealed a proviral effect of *AaeVLG-2*, but this remains to be more comprehensively investigated. The evolutionary analysis does not support the hypothesis of neofunctionalization of *VLG-1* following its duplication from *VLG-2*. We found that purifying selection remained the predominant mode of evolution for both paralogs after the duplication in the Culicinae. Neofunctionalization is typically associated with relaxed purifying selection, including sites evolving under positive selection and diversification [46], as well as asymmetry in ω following the duplication event [47]. Our results are more consistent with subfunctionalization, whereby each paralog retains a subset of its original ancestral function. Under a subfunctionalization scenario, higher ω is expected in the daughter lineages compared to the parental lineage [47]. Moreover, *VLG-2* knockdown in *VLG-1*$^{\Delta}$ mutants resulted in a similar phenotype to *VLG-2* knockdown in wild-type controls and control knockdown in *VLG-1*$^{\Delta}$ mutants, suggesting a functional co-dependency of *VLG-2* and *VLG-1*, where both paralogs would provide their proviral activity jointly in *Ae. aegypti*. Subfunctionalization can also occur via specialization, a process in which paralogs divide into various areas of specialty, such as tissue-specificity, rather than function [48]. Additional evidence is needed to support a subfunctionalization scenario for *Vago*-like genes in *Ae. aegypti*.

366 In conclusion, our study unveils an unexpected proviral activity of the *Vago*-like gene *VLG-1*
367 during flavivirus infection in *Ae. aegypti*. Although the proviral effect of *VLG-1* does not seem
368 to significantly influence vector competence, our findings challenge the notion that genes of
369 the *Vago* family are conserved antiviral factors in arthropods and question their designation as
370 antiviral cytokines. We anticipate that our newly generated *VLG-1*$^{\Delta}$ mosquito mutant line will
371 serve as a valuable tool to investigate the function of *VLG-1* in *Ae. aegypti*. This work
372 underscores the importance of *in vivo* research for identifying and characterizing the biological
373 roles of pro- and antiviral factors that govern the ability of *Ae. aegypti* mosquitoes to transmit
374 arboviruses. This fundamental understanding of mosquito-arbovirus interactions will be critical
375 to the development of new strategies aiming to reduce the burden of arboviral diseases [49].

ACKNOWLEDGEMENTS

We thank Catherine Lallemand for assistance with mosquito rearing, Artem Baidaliuk for preliminary bioinformatic analysis of *Vago*-like gene homology, and Prasad Paradkar for kindly sharing the CxVLG-1 antibody. RNA-seq library preparation was performed by Elodie Turc and Laure Lemée from the Biomics platform (C2RT, Institut Pasteur, Paris, France) supported by France Génomique (ANR-10-INBS-09) and IBISA. This work was supported by the French Government's Investissement d'Avenir program, Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases (grant ANR-10-LABX-62-IBEID to L.L. and E.C.), Agence Nationale de la Recherche (grant ANR-18-CE35-0003-01 to L.L.), a PhD grant from Ecole Normale Supérieure de Lyon (to E.C.) and a junior seed grant from Institut Pasteur (to E.C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

AUTHOR CONTRIBUTIONS

Conceptualization: E.C., J.D., P.M., T.V., S.H.M., L.L.
Investigation: E.C., A.B.C., J.D., A.B., F.A.H.v.H., U.P., T.V., S.D.
Data curation: H.V.
Formal analysis: E.C., H.V., J.D., F.A.H.v.H., A.B., U.P., L.L.
Visualization: E.C., F.A.H.v.H., H.V.
Writing – original draft: E.C., S.H.M., L.L.
Writing – review and editing: E.C., P.M., S.H.M., L.L.
Funding acquisition: E.C., S.H.M., L.L.

397 **METHODS**

398 **Virus strains**

399 DENV-1 strain KDH0026A was originally isolated in 2010 from the serum of a patient in
400 Kamphaeng Phet, Thailand [52]. ZIKV strain Kedougou2011 was originally isolated in 2011
401 from a mosquito pool in Kedougou, Senegal [53]. Viral stocks were prepared in C6/36 *Aedes*
402 *albopictus* cells as previously described [54].

403

404 **Mosquitoes**

405 Experiments were conducted with a previously described isofemale line of *Ae. aegypti* called
406 Jane [19, 55]. Mosquitoes were reared in controlled conditions (28°C, 12-hour light/12-hour
407 dark cycle and 70% relative humidity). For experiments, eggs were hatched synchronously in
408 a SpeedVac vacuum device (Thermo Fisher Scientific) for 45 minutes. Larvae were reared in
409 plastic trays containing 1.5 L of dechlorinated tap water and fed a standard diet of Tetramin
410 (Tetra) fish food at a density of 200 larvae per tray. After emergence, adults were kept in
411 BugDorm-1 insect cages (BugDorm) with permanent access to 10% sucrose solution.

412

413 **CRISPR/Cas9-mediated gene editing**

414 ***sgRNA design and synthesis.*** A *VLG-1* mutant line and wild-type "sister" line were derived
415 from the 26th generation of the Jane isofemale line. Gene editing was performed using
416 CRISPR/Cas9 technology as previously described [56]. The single-guide RNAs (sgRNAs)
417 were designed using CRISPOR [57] by searching for 20-bp sgRNAs with the NGG
418 protospacer-adjacent-motif (PAM). To reduce chances of off-target mutations, only sgRNAs
419 with off-target sites with at least four mismatches were selected. Three sgRNAs were selected
420 with cut sites respectively located upstream of the start codon, in the middle of the *VLG-1* gene
421 within the second exon, and upstream of the stop codon. Since the *VLG-1* locus is only 471-
422 bp (including introns), a single-stranded oligodeoxynucleotide (ssODN) repair template was
423 provided to delete the entire gene. The ssODN repair template included two 35-bp homology
424 arms matching the sequence upstream from the cut site of the first sgRNA (x1_30rev) and
425 downstream from the cut site of the third sgRNA (x3_67rev) to facilitate excision of the *VLG-1*
426 gene. The ssODN repair template was synthesized and PAGE-purified commercially (Sigma-
427 Aldrich). Single-guide RNAs were synthetized with the with MEGAscript T7 *in vitro* transcription
428 kit (Ambion) and purified with the MEGAclear kit (Invitrogen).

429 ***Embryonic microinjections.*** *Ae. aegypti* embryos were injected with a microinjection mix
430 containing 402.5 ng/µL SpCas9 protein (New England Biolabs), 40 ng/µL of each of three
431 sgRNAs (x1_30rev, x2_6rev, x3_67rev), and 125 ng/µL of the ssODN repair template
432 suspended in molecular grade water. The microinjection of *Ae. aegypti* embryos was
433 performed using standard protocols [58]. *Ae. aegypti* adult females were bloodfed with

434 commercial rabbit blood (BCL) via an artificial membrane feeding system (Hemotek). Three
435 days post bloodmeal, females were transferred to egg-laying vials and oviposition was induced
436 by placing mosquitoes into dark conditions for 15 min. Embryos were injected 30-60 min post
437 oviposition. Embryos were hatched in water 3 days post injection and individual pupae placed
438 into vials containing a small amount of water to isolate and screen adults for mutations before
439 mating could occur.
440 ***Mutation isolation and line creation.*** Individual virgin adult G_0 mosquitoes were screened
441 for mutations by PCR to amplify the *VLG-1* gene from DNA extracted from a single leg (see
442 Genotyping below). The amplified region was 793 bp and deletions were screened for on a 2%
443 agarose gel. If large deletions were detected, the corresponding mosquito was mated with
444 wild-type mosquitoes of the opposite sex and progeny screened for inheritance of the mutation.
445 Sanger sequencing was then performed to characterize the edit. A large deletion of ~200 bp
446 was identified in a G_0 female that was subsequently placed in a cage with 3 wild-type males
447 for mating, blood feeding, and egg laying. The G_1 eggs were hatched in water 5 days post
448 laying and individual pupae isolated into vials containing a small amount of water to isolate
449 and screen adults for mutations before mating could occur. G_1 progeny was screened for the
450 deletion by PCR to confirm heritability of the mutation. Four G_1 males (heterozygous for the
451 mutation) were then crossed with 50 wild-type females. Next, 11 G_2 male heterozygotes were
452 crossed with 23 wild-type females. Finally, 14 G_3 males and 33 G_3 females heterozygous at the
453 mutation site were crossed with each other. G_4 adults were sorted into homozygous mutants
454 (establishing the *VLG-1*$^{\Delta}$ mutant line) and homozygous wild types (establishing the control
455 "sister" line). The *VLG-1*$^{\Delta}$ mutant line was established with 9 G_4 males and 24 G_4 females, while
456 the control line was established with19 males and 29 females. Sequencing of *VLG-1*$^{\Delta}$
457 individuals using Sequencing primer F (Supplementary Table 5) revealed that the deletion
458 spanned 246 bp of the wild-type *VLG-1* sequence starting at the cut site of the sgRNA in the
459 middle of the gene (x2_6rev), 170 bp downstream of the still intact start codon, and ending at
460 the cut site of the third sgRNA (x3_67rev), 49 bp upstream of the stop codon. However, the
461 mutation also contained a 34-bp insertion of the upstream 35-bp homology arm of the repair
462 template in-between the sgRNA cut sites, resulting in a PCR product 212-bp shorter than the
463 wild-type PCR product, matching what was visualized on gels during screening.
464 ***Genotyping.*** Genomic DNA was extracted from single legs of individual mosquitoes using
465 DNAzol DIRECT (DN131, Molecular Research Center, Inc.). To obtain legs from live
466 mosquitoes, pupae were placed in vials containing a small volume of water and sealed with a
467 cotton plug (Flugs, Genesee). After adult emergence, the water was drained and vials placed
468 on ice for anesthesia. Single legs were collected using forceps and placed in a 2-mL screw-
469 top plastic tube containing ~20 1-mm glass beads (BioSpec) and 200 µL of DNAzol DIRECT.
470 Mosquitoes were then placed back into the vials to remain isolated and unmated until

471 genotyping via PCR. The legs were homogenized for 30 sec at 6,000 revolutions per minute
472 (rpm) in a Precellys 24 tissue homogenizer (Bertin Technologies), briefly centrifuged, and then
473 placed at room temperature (20-25°C) for immediate use. PCR was performed using
474 DreamTaq DNA Polymerase (EP0701, Thermo-Fisher Scientific) based on manufacturer's
475 instructions, using Genotyping primers (Supplementary Table 5). Approximately 0.6 µL of the
476 DNAzol DNA extract from leg tissue was used in 19 µL of DreamTaq PCR master mix. The
477 PCR conditions were as follows: initial denaturation at 95°C for 3 min, 40 cycles of amplification
478 (denaturation at 95°C for 30 sec, annealing at 59°C for 15 sec, and extension at 72°C for 30
479 sec), and a final extension step at 72°C for 5 min. Amplicons were purified (MinElute PCR
480 purification kit, Qiagen) and subsequently sequenced (Eurofins).
481
482 **Evolutionary analyses**
483 ***Gene phylogeny.*** Using the protein sequence of *AaeVLG-1* (*AAEL000200;* RefSeq accession
484 number XP_001658930.1) and *AaeVLG-2* (*AAEL000165;* RefSeq accession number
485 XP_001658929.1) as queries, we performed a BLASTP against the NCBI non-redundant
486 protein database to extract homologous genes present in the *Drosophila* genus and Culicidae
487 family. Only genes present in the reference sequence (RefSeq) were considered in the final
488 dataset of 62 homologous genes (Supplementary Table 2). Then, input coding sequences were
489 aligned with respect to their codon structure using MACSE v2.06 [59] and the protein alignment
490 was used as input for IQ-tree2 [60] to infer the phylogenetic relationships of the *Vago*-like gene
491 homologs. The substitution model WAG+I+G4 was the best fit model based on the Bayesian
492 Information Criterion (BIC) and the maximum-likelihood phylogenetic tree was generated with
493 1,000 ultra-fast bootstrap iterations. The phylogenetic tree of *Vago*-like genes was rooted using
494 *Drosophila* sequences and visualized using iTOL [61].
495 ***Evolutionary rate.*** To investigate the evolutionary rates of *Vago*-like gene coding sequences,
496 the CODEML tool from the PAML package [62] was used to detect variations of the ratio of
497 non-synonymous to synonymous substitutions (ω) as a proxy for the variation in selective
498 pressure, following the guide for user good practices [63]. CODEML was configured to use the
499 branch model, which assumes different ω parameters for different branches in the phylogeny
500 [64, 65]. Three tests were conducted by designating different branches as the foreground: (i)
501 *VLG-1* branch, (ii) both *VLG* and *VLG-1* branches, (iii) *VLG-1*, Anophelinae *VLG* and Culicinae
502 *VLG* branches. Comparison of the branch model to the null model was performed through a
503 likelihood-ratio test (Supplementary Table 3).
504
505 **Mosquito fitness assays**
506 ***Survival.*** Five to seven days after adult emergence, males and females were sorted and
507 transferred in 1-pint carton boxes with permanent access to 10% sucrose solution at 28°C and

508 70% relative humidity. Mortality was scored daily. Four replicate boxes containing 25
509 mosquitoes each were used for each experiment.
510 ***Fecundity*.** Five- to seven-day-old females were blood fed and transferred to individual vials
511 containing a humid blotting paper for egg laying with access to 10% sucrose solution. After 7
512 days, eggs deposited on the blotting paper were counted under a binocular magnifier.
513 Fecundity was defined as the number of eggs laid per blood-fed female.
514 ***Fertility*.** The aforementioned blotting papers air dried for a week. Eggs were then hatched
515 synchronously in a SpeedVac vacuum device (Thermo Fischer Scientific) for 45 min. Larvae
516 were transferred to individual vials containing tap water and with Tetramin fish food, and viable
517 larvae were enumerated three days later. Fertility was defined as the number of viable larvae
518 over the total number of laid eggs per blood-fed female.
519
520 **Mosquito infectious bloodmeals**
521 Experimental infections of mosquitoes were performed in a biosafety level-3 containment
522 facility, as previously described [54]. Shortly, 5- to 7-day-old female mosquitoes were deprived
523 of 10% sucrose solution 20 hours prior to being exposed to an artificial infectious bloodmeal
524 containing 5×10^6 FFU/mL of DENV-1 or 5×10^5 PFU/mL of ZIKV. The infectious bloodmeal
525 consisted of a 2:1 mix of washed rabbit erythrocytes (BCL) supplemented with 10 mM
526 adenosine triphosphate (Sigma) and viral suspension supplemented with Leibovitz's L-15
527 medium (Gibco; described below). Mosquitoes were exposed to the infectious bloodmeal for
528 15 min through a desalted pig-intestine membrane using an artificial feeder (Hemotek Ltd) set
529 at 37°C. Fully blood-fed females were sorted on ice and incubated at 28°C, 70% relative
530 humidity and under a 12-hour light-dark cycle with permanent access to 10% sucrose solution.
531
532 **Gene expression and viral load quantification**
533 Mosquito tissues were dissected in 1× phosphate-buffered saline (PBS), and immediately
534 transferred to a tube containing 400 µL of RA1 lysis buffer from the Nucleospin 96 RNA core
535 kit (Macherey-Nagel) and ~20 1-mm glass beads (BioSpec). Samples were homogenized for
536 30 sec at 6,000 rpm in a Precellys 24 grinder (Bertin Technologies). RNA was extracted and
537 treated with DNase I following the manufacturer's instructions. Viral RNA was reverse
538 transcribed and quantified using a TaqMan-based qPCR assay, using virus-specific primers
539 and 6-FAM/BHQ-1 double-labelled probe (Supplementary Table 5). Reactions were performed
540 with the GoTaq Probe 1-Step RT-qPCR System (Promega) following the manufacturer's
541 instructions. Viral RNA levels were determined by absolute quantification using a standard
542 curve. The limit of detection was of 40 copies of viral RNA per microliter. Transcript RNA levels
543 were normalized to the housekeeping gene encoding ribosomal protein S 17 (*RPS17*), and
544 expressed as 2^{-dCt}, where $dCt = Ct_{Gene} - Ct_{RPS17}$.

545 **Virus titration**

546 ***Focus-forming assay (FFA).*** DENV infectious titers were measured by standard FFA in C6/36
547 cells. Cells were seeded at a density of $5x10^4$ cells/well in a 96-well plate 24 hours before
548 inoculation. Serial sample dilutions were prepared in Leibovitz's L-15 medium (Gibco)
549 supplemented with 0.1% penicillin/streptomycin (pen/strep; Gibco ThermoFisher Scientific),
550 2% tryptose phosphate broth (TBP; Gibco Thermo Fischer Scientific), 1× non-essential amino
551 acids (NEAA; Life Technologies) and 2% fetal bovine serum (FBS; Life Technologies). Cells
552 were inoculated with 40 µL of sample. After 1 hour of incubation at 28°C, the inoculum was
553 replaced with 150 µL of overlay medium (1:1 mix of Leibovitz's L-15 medium supplemented
554 with 0.1% pen/strep, 2% TPB, 1× NEAA, 2× Antibiotic-Antimycotic [Life Technologies], 10%
555 FBS and 2% carboxyl methylcellulose) and incubated for 5 days at 28°C. Cells were fixed for
556 30 min in 3.6% paraformaldehyde (PFA; Sigma-Aldrich). Cells were then washed three times
557 with PBS 1×, and permeabilized for 30 min with 50 µL of PBS 1×; 0.3% Triton X-100 (Sigma-
558 Aldrich) at room temperature (20-25°C). The cells were washed three times in PBS 1× and
559 incubated for 1 hour at 37°C with 40 µL of mouse anti-DENV complex monoclonal antibody
560 MAB8705 (Merck Millipore) diluted 1:200 in PBS 1×; 1% bovine serum albumin (BSA)
561 (Interchim). After another three washes in PBS, cells were incubated at 37°C for 30 min with
562 40 µL of an Alexa Fluor 488-conjugated goat anti-mouse antibody (Life Technologies) diluted
563 1:500 in PBS 1×; 1% BSA. After three washes in PBS 1× and a final wash in water, infectious
564 foci were counted under a fluorescent microscope (Evos) and converted into focus-forming
565 units/mL (FFU/mL).

566 ***Plaque assay.*** ZIKV infectious titers were measured by plaque assay in Vero E6 cells. Cells
567 were seeded in 24-well plates at a density of 150,000 cells/well 24 hours before inoculation.
568 Ten-fold sample dilutions were prepared in Dulbecco's Modified Eagle Medium (DMEM) with
569 2% FBS, 1% pen/strep, 4× Antibiotic-Antimycotic and cells were incubated with 200 µL of
570 inoculum. After 1 hour at 37°C, the inoculum was replaced with DMEM supplemented with 2%
571 FBS, 1% pen/strep, 4× Antibiotic-Antimycotic and 0.8% agarose. Cells were fixed with 3.6%
572 PFA after 6 days and plaques were counted manually after staining with 0.1% crystal violet
573 (Sigma).

574

575 **Salivation assay**

576 Mosquitoes were anesthetized with triethylamine (≥99%, Sigma-Aldrich) for 10 min and their
577 legs were removed. The proboscis of each female was inserted into a 20-µL pipet tip containing
578 10 µL of FBS for 30 min at room temperature (20-25°C). Saliva-containing FBS was expelled
579 into 90 µL of Leibovitz's L-15 medium supplemented with 0.1% pen/strep, 2% TPB, 1× NEAA
580 and 4× Antibiotic-Antimycotic. Virus presence in saliva samples was determined by virus

581 titration after 5 days of amplification in C6/36 cells. Transmission potential was assessed
582 qualitatively based on the presence or absence of infectious virus.
583
584 **Transcriptome analysis**
585 ***Library preparation and mRNA sequencing***
586 Total RNA extracts from pools of 10 tissues were isolated with TRIzol (Invitrogen) as previously
587 described [66] and treated with DNA-free kit (Invitrogen, AM1906) following the manufacturer's
588 instructions. The quality of the samples was assessed using a BioAnalyzer RNA Nano kit
589 (Agilent Technologies). RNA libraries were built using an Illumina Stranded mRNA library
590 Preparation Kit (Illumina) following the manufacturer's protocol depending on the insert size
591 required. Of note, to obtain 300-bp inserts, all the samples were eluted for 2 minutes at 80°C
592 after polyA capture, instead of the 8-min fragmentation at 94°C recommended by the supplier.
593 Sequencing was performed on two lanes 10B300 of NovaSeqX (Illumina) by Novogene.
594
595 ***Bioinformatics***
596 Raw RNA-seq reads were cleaned of adapter sequences and low-quality sequences using
597 cutadapt version 2.10 [67] with options "-m 25 -q 30 -O 6 --trim-n --max-n 1". Gene expression
598 quantification was performed using salmon version 1.9.0 [68]. First, the *Ae. aegypti* reference
599 transcriptome (downloaded from VectorBase (release 66)
600 at https://vectorbase.org/common/downloads/release-66/AaegyptiLVP_AGWG/fasta/data/)
601 was indexed along with its corresponding genome using the "--decoys" option. Transcript
602 expression was then quantified for each sample using the "-l A" option and summarized at the
603 gene level using the "--geneMap" parameter [69, 70]. Gene expression data was imported into
604 R version 4.3.2 [71] using the tximport package [72]. The normalization and dispersion
605 estimation were performed with DESeq2 [73] using the default parameters and statistical tests
606 for differential expression were performed applying the independent filtering algorithm. For
607 each tissue (bodies and midguts) at each time point (days 2, 5, and 9), a generalized linear
608 model was set to test for the mutation effect on gene expression, separately for infected and
609 non-infected mosquitoes. For each pairwise comparison, raw p-values were adjusted for
610 multiple testing according to the Benjamini and Hochberg procedure [74] and genes with an
611 adjusted p-value lower than 0.05 and an absolute fold-change higher than 2 were considered
612 differentially expressed.
613
614 **Gene set enrichment analysis**
615 Gene set enrichment analysis was performed using Fisher's statistical test for the over-
616 representation in differentially expressed genes. *Ae. aegypti* gene ontology (GO) annotations
617 [75] were retrieved from the VectorBase website (version 66). Only gene sets with a false

618 discovery rate (FDR) lower than 0.05 were considered significantly enriched in differentially
619 expressed genes.
620
621 **Gene knockdown assay**
622 Double-stranded RNA (dsRNA) targeting *AaeVLG-2* (AAEL000165) was *in vitro* transcribed
623 from T7 promoter-flanked PCR products using the MEGAscript RNAi kit (Life Technologies).
624 To obtain the PCR products, a first PCR was performed on genomic DNA extracted from wild-
625 type mosquitoes using the previously described Pat-Roman DNA extraction protocol [76]. The
626 T7 sequence was then introduced during a second PCR using T7 universal primers that
627 hybridize to short GC-rich tags introduced to the PCR products in the first PCR (Supplementary
628 Table 5). dsRNA targeting *Luciferase* (as a negative control) was synthesized using T7
629 promoter-flanked PCR products generated by amplifying a *Luciferase*-containing plasmid with
630 T7-flanked PCR primers with the MEGAscript RNAi kit (Life Technologies) (Supplementary
631 Table 5). dsRNA was resuspended in RNase-free water to reach a final concentration of
632 10 mg/mL. Five- to seven-day-old females were anesthetized on ice and injected
633 intrathoracically with 1 µg (in a volume of 100 nL) dsRNA suspension using a Nanoject III
634 apparatus (Drummond). After injection, mosquitoes were incubated for 2 days at 28°C before
635 the infectious bloodmeal. The knockdown efficiency was estimated by RT-qPCR on the day of
636 the bloodmeal as (1 – ddCt)*100, where ddCt = (mean (2^{-dCt} in ds*VLG-2* condition)) / (mean (2^{-}
637 ^{dCt} in ds*Luciferase* condition)), and dCt = Ct_{VLG-2} – Ct_{RPS17}.
638
639 **Western blotting**
640 Five female mosquitoes were collected in 250 µL of 2× RIPA buffer complemented with
641 protease inhibitor (Complete 1×, Roche) in tubes containing ~20 1-mm glass beads (BioSpec).
642 Samples were homogenized for 30 sec at 6,000 rpm in a Precellys 24 grinder (Bertin
643 Technologies). Lysates were clarified by centrifugation at 14,000 rpm for 5 min at 4°C and kept
644 on ice. Fifty microliters of lysate were heated at 95°C with 50 µL of Laemmli buffer for 5 min.
645 Twenty microliters of denatured samples were loaded on a PROTEAN TGX 4-20% stain-free
646 precast gel (Biorad) in 1× Tris-Glycine-SDS running buffer (Alfa Aesar). Transfer on a
647 nitrocellulose membrane was done using a Trans-Blot Turbo transfer pack (Biorad) for 30 min
648 at 25 V. The membrane was then incubated in PBS 1×-Tween 0.1%-powdered milk (Régilait)
649 5% (PBST-milk) for 1 hour. Incubation with the primary antibody (rabbit anti-CxVLG-1
650 (GenScript) generated in [26], 1:2,000 in PBST-milk) was done for 1 hour at room temperature
651 (20-25°C) before washing three times for 5 min in PBST. The anti-CxVLG-1 antibody targets
652 the C-terminal sequence CEKIKQDLTKDYPE which is located within the deleted region in the
653 *VLG-1*$^{\Delta}$ mutant sequence. The membrane was then incubated in the secondary antibody

(donkey anti-rabbit, ab216779, 1:20,000 in PBST-milk) for 1 hour at room temperature. After three washes of 5 min in PBST, the membrane was imaged on an Odyssey LICOR imager.

Promoter analysis

To analyze the presence of transcription factor (TF) binding motifs in the promoter of *VLG-1*, we used MoLoTool (https://molotool.autosome.org/), which contains 1443 verified position weight matrices from the HOCOMOCO H12CORE collection [77]. Motifs were searched for within the 500 bp upstream and 50 bp downstream regions of the *VLG-1* transcription start site. Matched motifs were considered as hits after multiple testing correction using the Bonferroni method. Before visualization of the motifs on the *VLG-1* promoter, redundancy was addressed by merging hits from the same TF family overlapping more than 50% in position, as well as merging similar TF families into categories.

Statistics

Gene expression data were analyzed by one-way analysis of variance (ANOVA) after $\log_{10}$-transformation of the 2^{-dCt} values, followed by Tukey-Kramer's Honest Significant Difference (HSD) test. Viral loads, knockdown efficiency, and fecundity estimates were compared pairwise with a Mann-Whitney's non-parametric test. Proportions (midgut prevalence, carcass prevalence, carcass-to-head dissemination prevalence, transmission efficiency, fertility) were analyzed using a chi-squared non-parametric test. Survival assays were analyzed with a Gehan-Breslow-Wilcoxon test. Gene set enrichment analysis in the transcriptomic dataset was performed with Fisher's statistical test. Only genes with FDR < 0.05 were considered significantly enriched. Statistical analyses were performed in Prism v.10.1.0 (www.graphpad.com), JMP v.14.0.0 (www.jmp.com), and R v.4.3.2 (www.r-project.org).

Data availability

The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus [78] and are accessible through GEO Series accession number GSE269945.

682 **FIGURE LEGENDS**

683

684 **Figure 1. *VLG-1* is a *Vago*-like gene specific to the Culicinae subfamily.**

685 (A) Schematic cladogram of the evolutionary history of *Vago*-like gene homologs in Culicidae
686 and *Drosophila* species. The putative origin of duplication of *VLG-1* from the ancestral *VLG,*
687 inferred from the phylogenetic analysis of *Vago*-like gene homologs (Supplementary Figure
688 S1), is indicated with a blue arrow, whereas putative losses of *VLG-1* are indicated with blue
689 crosses. *AaeVLG-2* and *AaeVLG-1* are represented with black-striped yellow and blue
690 squares, respectively. (B) Amino-acid sequence alignment of *Ae. aegypti* VLG-1 (AaeVLG-1,
691 XP 001658930.1) and VLG-2 (isoform RB, XP 001658929.1) proteins with *D. melanogaster*
692 Vago (DmVago, NP_001285106.1), *D. melanogaster* VLG (DmVLG, NP_001097586) and
693 *Culex quinquefasciatus* VLG-1 (XP_001842264). The percentage of identity shared between
694 all sequences for each amino-acid position is represented by shades of colors, ranging from
695 light purple (when 3 out of 5 sequences are identical) to dark purple (when all 5 sequences are
696 identical). The conserved cysteine residues typical of SVWC domains are indicated by blue
697 arrows. (C) Functional domains of AaeVLG-1 with amino-acid (aa) positions. (D) Predicted 3D
698 structure of AaeVLG-1 protein obtained with Alphafold
699 (https://alphafold.ebi.ac.uk/entry/Q17PX2) [50, 51].

700

701 **Figure 2. *VLG-1* is persistently induced by bloodmeal ingestion and DENV exposure in**
702 **non-midgut tissues of *Ae. aegypti*.**

703 Expression levels of *AaeVLG-1* (A-C) and *AaeVLG-2* (D-F) were quantified by RT-qPCR in
704 midguts (A,D), carcasses (B,E), and heads (C,F) on 0, 2, 7, and 9 days after ingestion of a
705 mock or DENV-1 infectious bloodmeal, in mosquitoes of the wild-type control line. Gene
706 expression levels are normalized to the ribosomal protein S 17 housekeeping gene (*RPS17*),
707 and expressed as 2^{-dCt}, where $dCt = Ct_{Gene} - Ct_{RPS17}$. Each dot represents an individual tissue.
708 Horizontal bars represent medians and vertical bars represent 95% confidence intervals.
709 Statistical significance was determined by a one-way ANOVA after log_{10}-transformation of the
710 2^{-dCt} values, followed by Tukey-Kramer's HSD test. Statistical significance is represented
711 above the graph using letters; groups that do not share a letter are significantly different.

712

713 **Figure 3. *VLG-1*$^{\Delta}$ mutants are viable and fertile without major fitness defects.**

714 (A) Structure of the *VLG-1* locus in the wild-type control and the *VLG-1*$^{\Delta}$ mutant lines. Exons
715 are displayed as light blue boxes, connected by black segments representing introns. The
716 positions and cut-sites of single-guide RNAs are depicted on each exon. (B) Structure of the
717 VLG-1 protein in the wild-type control line and the *VLG-1*$^{\Delta}$ mutant line. (C-D) Survival curves
718 of adult males (C) and females (D) from the wild-type control (grey) and *VLG-1*$^{\Delta}$ mutant (blue)

719 lines in standard insectary conditions. Data represent mean and standard deviation of 4
720 replicates performed with 25 mosquitoes for each condition. *p<0.05; ***p<0.001 (Gehan-
721 Breslow-Wilcoxon test). (E) Fecundity (number of eggs laid per individual blood-fed female for
722 7 days after a bloodmeal) in the *VLG-1*$^{\Delta}$ mutant and control lines. Data represents mean and
723 standard deviation of 28 mosquitoes. *p<0.05; **p<0.01; ***p<0.001 (Mann-Whitney's test). (F)
724 Fertility (number of viable hatched larvae over the total number of eggs laid) in the *VLG-1*$^{\Delta}$
725 mutant and control lines. Data represent mean and standard errors of 26 mosquitoes. *p<0.05;
726 **p<0.01; ***p<0.001 (chi-squared test).
727
728 **Figure 4. *VLG-1* promotes systemic DENV dissemination in *Ae. aegypti*.**
729 (A-F) Female mosquitoes from the control (grey) and *VLG-1*$^{\Delta}$ mutant (blue) lines were offered
730 an infectious bloodmeal containing 5×10^6 FFU/mL of DENV-1. DENV-1 infection prevalence
731 (A-C) and non-zero viral loads (D-F) were measured by RT-qPCR in the midgut, carcass, and
732 head of individual mosquitoes on days 2, 5, and 9 post bloodmeal. (A-C) Midgut infection
733 prevalence was calculated as the number of virus-positive midguts over the total number of
734 virus-exposed mosquitoes. Carcass dissemination prevalence was calculated as the number
735 of virus-positive carcasses over the number of virus-positive midguts. Carcass-to-head
736 dissemination prevalence was calculated as the number of virus-positive heads over the
737 number of virus-positive carcasses. (D-F) Each dot represents an individual tissue. The
738 horizontal black lines represent the median values. *p<0.05; **p<0.01; ***p<0.001 (Mann-
739 Whitney's test). (G) Saliva samples from virus-exposed mosquitoes were collected on days 7,
740 10, and 14 after exposure and infectious virus particles in the saliva were detected by focus-
741 forming assay. In (A-C) and (G), vertical error bars represent the 95% confidence intervals of
742 the proportions. *p<0.05; **p<0.01; ***p<0.001 (chi-squared test). In (A-F), data from two
743 experimental replicates, analyzed and displayed separately because a significant experiment
744 effect was detected, are plotted using two shades of the same color.
745
746 **Figure 5. *VLG-1* promotes systemic ZIKV dissemination in *Ae. aegypti*.**
747 (A-F) Female mosquitoes from the control (grey) and *VLG-1*$^{\Delta}$ mutant (blue) lines were offered
748 an infectious bloodmeal containing 5×10^5 PFU/mL of ZIKV. ZIKV infection prevalence (A-C)
749 and non-zero viral loads (D-F) were measured by RT-qPCR in the midgut, carcass, and head
750 of individual mosquitoes on days 2, 5, and 9 post bloodmeal. (A-C) Midgut infection prevalence
751 was calculated as the number of virus-positive midguts over the total number of virus-exposed
752 mosquitoes. Carcass dissemination prevalence was calculated as the number of virus-positive
753 carcasses over the number of virus-positive midguts. Carcass-to-head dissemination
754 prevalence was calculated as the number of virus-positive heads over the number of virus-
755 positive carcasses. (D-F) Each dot represents an individual tissue. The horizontal black lines

represent the median values. *p<0.05; **p<0.01; ***p<0.001 (Mann-Whitney's test). (G) Saliva samples from virus-exposed mosquitoes were collected on days 7, 10, and 14 after exposure and infectious virus particles in the saliva were detected by focus-forming assay. In (A-C) and (G), vertical error bars represent the 95% confidence intervals of the proportions. *p<0.05; **p<0.01; ***p<0.001 (chi-squared test).

Figure 6. The transcriptome of *VLG-1$^{\Delta}$* mutants is broadly altered.

Female mosquitoes of the control and *VLG-1$^{\Delta}$* mutant lines were offered a mock or infectious bloodmeal containing 5×10^{6} FFU/mL of DENV-1. On days 2, 5, and 9 post bloodmeal, 3 pools of 10 tissues (midguts or bodies) were collected and analyzed by RNA-seq. (A-B) Number of differentially expressed genes (DEGs) in *VLG-1$^{\Delta}$* mutants compared to wild-type controls in midguts (A) and bodies (B) for both directions of change (up- or down-regulated). A gene was considered DEG when the absolute fold change was ≥ 2 and the adjusted p-value was ≤ 0.05. (C-D) Venn diagrams showing the overlap of up-regulated (C) and down-regulated (D) genes in *VLG-1$^{\Delta}$* mutants compared to controls between all combinations of midguts, bodies, and bloodmeal type, on day 2 post bloodmeal. (E) Gene ontology (GO) enrichment of DEGs in *VLG-1$^{\Delta}$* mutants compared to controls for both bloodmeal types, in midguts and bodies. Fold enrichment of each GO term is represented by a circle whose size is inversely proportional to the false discovery rate (FDR) of the enrichment score. GO terms with a similar biological function are identified with a color code and assigned a higher-order functional annotation. Correspondence between GO term names and IDs are listed in Supplementary Table 4.

SUPPLEMENTARY FIGURES LEGENDS

Supplementary figure S1. **Phylogenetic tree of *Vago*-like gene homologs among Culicidae and *Drosophila* species.** The tree was constructed with a maximum-likelihood analysis of amino-acid sequences with at least 30% identity with *D. melanogaster VLG* (*DmVLG*, CG14132). Accession number (RefSeq) of the homolog protein and name of the species are indicated at the tip of each branch. *VLG* and *VLG-1* clades are colored in yellow and blue, respectively. The size of blue dots represents the bootstrap support of each node. The dN/dS (ω) estimates are indicated for the main branches.

Supplementary figure S2. Evidence for *VLG-1* loss of function in mutant *Ae. aegypti*. (A) *AaeVLG-1* transcript expression levels detected by RT-qPCR in the control and *VLG-1*$^{\Delta}$ mutant lines. ****p<0.0001 (Mann-Whitney's test) (B) Coverage (number of reads per nucleotide position) of *AaeVLG-1* transcripts by RNA-seq in *VLG-1*$^{\Delta}$ mutants (top panels) and controls (bottom panels) in three pools of 10 bodies for each line. (C) Western blotting of VLG-1 protein using an anti-CxVLG-1 antibody in controls and *VLG-1*$^{\Delta}$ mutants, in four pools of five females for each line. The band corresponding to VLG-1 theoretical size (15 kiloDaltons (kDa)) is highlighted in red and is detected in the controls but not in the *VLG-1*$^{\Delta}$ mutants. (D) *AaeVLG-2* transcript expression levels detected by RT-qPCR in the control and *VLG-1*$^{\Delta}$ mutant lines. (E) Number of reads of *AaeVLG-1* and *AaeVLG-2* transcripts detected by RNA-seq in bodies of controls and *VLG-1*$^{\Delta}$ mutants on days 2, 5, and 9 after a mock bloodmeal. Mean normalized counts (obtained with DESeq2 [73]) from three pools of 10 bodies for each line are depicted. Vertical bars represent standard deviations. In (A) and (D), gene expression levels are normalized to the transcript abundance of the housekeeping gene encoding ribosomal protein S 17 (*RPS17*), and expressed as 2^{-dCt}, where $dCt = Ct_{Gene} - Ct_{RPS17}$.

Supplementary figure S3. *AaeVLG-2* knockdown reduces the proportion of DENV-positive heads. Female *Ae. aegypti* from both the *VLG-1*$^{\Delta}$ mutant line and the control line were injected with either dsRNA targeting *AaeVLG-2* or a dsRNA targeting the *Luciferase* gene as a negative control. Forty-eight hours after injection (on the day of the infectious bloodmeal), mosquitoes were offered an infectious bloodmeal containing 5×10^6 FFU/mL of DENV-1. Heads were collected on day 7 after the bloodmeal and processed for viral RNA quantification to evaluate infection prevalence (A) and viral loads (B). In parallel, whole unfed mosquitoes were collected on the day of the bloodmeal to quantify *AaeVLG-2* transcript RA (C) and transcript RB (D) abundance by RT-qPCR. Gene expression levels are normalized to the transcript abundance of the housekeeping gene encoding ribosomal protein S 17 (*RPS17*), and

813 expressed as 2^{-dCt}, where dCt = Ct_{Gene} – Ct_{RPS17}. *p<0.05; **p<0.01; ***p<0.001 (Mann-
814 Whitney's test for gene knockdown efficiency and viral loads, chi-squared test for prevalence).
815
816 **Supplementary figure S4. Overlap of differentially expressed genes in *VLG-1$^{\Delta}$* mutants**
817 **compared to wild-type controls on days 5 and 9 post bloodmeal.** Venn diagrams show the
818 number of up-regulated (A, C) and down-regulated (B, D) differentially expressed genes
819 shared between experimental conditions on day 5 (A-B) and day 9 (C-D) post bloodmeal.
820
821 **Supplementary figure S5. Volcano plots of differentially expressed genes in *VLG-1$^{\Delta}$***
822 **mutants compared to wild-type controls in the DENV-exposed condition.** Statistical
823 significance of the difference in gene expression between mutants and controls (adjusted for
824 multiple testing) is shown as a function of the log_2-transformed fold change in expression.
825 Genes that are significantly up-regulated and down-regulated are shown in red and blue,
826 respectively. Comparisons were performed separately by tissue ((A, C, E): midgut; (B, D, F):
827 body) and timepoint ((A-B): day 2; (C-D): day 5; (E-F): day 9 post bloodmeal). When detected,
828 *AAEL000200* was removed from the plot to avoid graphical distortion due to its extremely low
829 expression in *VLG-1$^{\Delta}$* mutants.
830
831 **Supplementary figure S6. Transcription factor binding motifs found in the *Ae. aegypti***
832 ***VLG-1* promoter sequence.** Motif hits identified and classified per transcription factor family
833 in the promoter region (500 bp upstream and 50 bp downstream of the *VLG-1* transcription
834 start site (TSS) (TSS coordinates: chr3:215,597,712). Nucleotide position is indicated relative
835 to the TSS. The Znf (others) category includes the "Other with up to three adjacent zinc
836 fingers", "More than 3 adjacent zinc fingers" and "Multiple dispersed zinc fingers" transcription
837 factor families. The "Hormone-receptor related" category includes the "Steroid hormone
838 receptors", "Thyroid hormone receptor-related" and "RXR-related receptors" families. The
839 number of identified motifs is indicated for each motif category.

840 **SUPPLEMENTARY TABLES**

841 **Supplementary Table 1. Proposed updated designation of *Vago* and *Vago*-like genes.**

Species	Previous designation	New proposed designation	Refs
Drosophila melanogaster	*DmVago (CG2081)*	*DmVago (CG2081)*	[25]
	CG14132	*DmVLG (CG14132)*	-
Culex quinquefasciatus	*CxVago1 (CQUJHB003889)*	*CxVLG-1 (CQUJHB003889)*	[26,27]
Aedes aegypti	*AaeVago1 (AAEL000200)*	*AaeVLG-1 (AAEL000200)*	[28]
	AaeVago2 (AAEL000165)	*AaeVLG-2 (AAEL000165)*	[28]

842

843 **Supplementary Table 2. *Vago*-like gene homologs used in the gene phylogeny.**

Locus ID	Species	Taxa id	Genomic_nucleotide_accession.version	Sequence ID	Family	SubFamily	group
LOC5570039	Aedes aegypti	7159	NC_035109.1	NC_035109.1_cds_XP_001658929.1_4926	Culicidae	Culicinae	B
LOC5570040	Aedes aegypti	7159	NC_035109.1	NC_035109.1_cds_XP_001658930.1_4928	Culicidae	Culicinae	A
LOC109400458	Aedes albopictus	7160	NC_085138.1	NC_085138.1_cds_XP_029709764.1_5850	Culicidae	Culicinae	B
LOC115253693	Aedes albopictus	7160	NC_085138.1	NC_085138.1_cds_XP_062715345.1_5797	Culicidae	Culicinae	B
LOC115264547	Aedes albopictus	7160	NC_085138.1	NC_085138.1_cds_XP_029724200.2_5800	Culicidae	Culicinae	A
LOC120901461	Anopheles arabiensis	7173	NC_053518.1	NC_053518.1_cds_XP_040165364.1_4462	Culicidae	Anophelinae	B
LOC120901758	Anopheles arabiensis	7173	NC_053518.1	NC_053518.1_cds_XP_040165919.1_4461	Culicidae	Anophelinae	B
LOC120904171	Anopheles arabiensis	7173	NC_053518.1	NC_053518.1_cds_XP_040169915.1_4463	Culicidae	Anophelinae	B
LOC120959656	Anopheles coluzzii	1518534	NC_064671.1	NC_064671.1_cds_XP_040234707.2_4268	Culicidae	Anophelinae	B
LOC131264480	Anopheles coustani	139045	NC_071289.1	NC_071289.1_cds_XP_058122762.1_3080	Culicidae	Anophelinae	B
LOC131269784	Anopheles coustani	139045	NC_071290.1	NC_071290.1_cds_XP_058128284.1_136	Culicidae	Anophelinae	B
LOC128274233	Anopheles cruzii	68878	NC_069143.1	NC_069143.1_cds_XP_052868316.1_116	Culicidae	Anophelinae	B
LOC125956039	Anopheles darlingi	43151	NC_064873.1	NC_064873.1_cds_XP_049543457.1_501	Culicidae	Anophelinae	B
LOC4578297	Anopheles gambiae	7165	NC_064602.1	NC_064602.1_cds_XP_001238104.2_5216	Culicidae	Anophelinae	B
LOC126561500	Anopheles maculipalpis	1496333	NC_064870.1	NC_064870.1_cds_XP_050073643.1_391	Culicidae	Anophelinae	B
LOC128712963	Anopheles marshallii	1521116	NC_071325.1	NC_071325.1_cds_XP_053663807.1_1003	Culicidae	Anophelinae	B
LOC121597485	Anopheles merus	30066	NC_054084.1	NC_054084.1_cds_XP_041779213.1_4853	Culicidae	Anophelinae	B
LOC128729155	Anopheles nili	185578	NC_071293.1	NC_071293.1_cds_XP_053678784.1_673	Culicidae	Anophelinae	B
LOC118505143	Anopheles stephensi	30069	NC_050201.1	NC_050201.1_cds_XP_035896397.1_769	Culicidae	Anophelinae	B
LOC134219609	Armigeres subalbatus	124917	NC_085141.1	NC_085141.1_cds_XP_062554379.1_5609	Culicidae	Culicinae	A
LOC134219610	Armigeres subalbatus	124917	NC_085141.1	NC_085141.1_cds_XP_062554381.1_5607	Culicidae	Culicinae	B
LOC120416670	Culex pipiens pallens	42434	NC_068938.1	NC_068938.1_cds_XP_039434419.1_5341	Culicidae	Culicinae	B
LOC120416672	Culex pipiens pallens	42434	NC_068938.1	NC_068938.1_cds_XP_039434421.1_5342	Culicidae	Culicinae	B
LOC119767415	Culex quinquefasciatus	7176	NC_051862.1	NC_051862.1_cds_XP_038111890.1_4281	Culicidae	Culicinae	B
LOC6031460	Culex quinquefasciatus	7176	NC_051862.1	NC_051862.1_cds_XP_001842264.1_4279	Culicidae	Culicinae	A
LOC6042215	Culex quinquefasciatus	7176	NC_051863.1	NC_051863.1_cds_XP_001851356.2_1354	Culicidae	Culicinae	B
LOC117571568	Drosophila albomicans	7291	NC_047629.2	NC_047629.2_cds_XP_034109668.1_6313	Drosophilidae	Drosophilinae	C
LOC6507152	Drosophila ananassae	7217	NC_057928.1	NC_057928.1_cds_XP_001956579.2_3507	Drosophilidae	Drosophilinae	C
LOC108613639	Drosophila arizonae	7263	NW_017127684.1	NW_017127684.1_cds_XP_017862695.1_2490	Drosophilidae	Drosophilinae	C
LOC108124169	Drosophila bipectinata	42026	NW_025063860.1	NW_025063860.1_cds_XP_017095220.2_1735	Drosophilidae	Drosophilinae	C
LOC108599062	Drosophila busckii	30019	NC_046606.1	NC_046606.1_cds_XP_017841331.1_246	Drosophilidae	Drosophilinae	C
LOC108113944	Drosophila eugracilis	29029	NW_024573038.1	NW_024573038.1_cds_XP_017080144.1_1410	Drosophilidae	Drosophilinae	C
LOC6558867	Drosophila grimshawi	7222	NW_025063240.1	NW_025063240.1_cds_XP_001984323.1_1790	Drosophilidae	Drosophilinae	C
LOC117580089	Drosophila guanche	7266	NW_022995744.1	NW_022995744.1_cds_XP_034122233.1_1073	Drosophilidae	Drosophilinae	C
LOC111592799	Drosophila hydei	7224	NW_022045643.1	NW_022045643.1_cds_XP_023160974.2_1719	Drosophilidae	Drosophilinae	C
LOC117788884	Drosophila innubila	198719	NW_022995376.1	NW_022995376.1_cds_XP_034483707.1_2069	Drosophilidae	Drosophilinae	C
LOC108073886	Drosophila kikkawai	30033	NW_024571631.1	NW_024571631.1_cds_XP_017021160.1_246	Drosophilidae	Drosophilinae	C
LOC108151958	Drosophila miranda	7229	NC_046674.1	NC_046674.1_cds_XP_017136386.1_158	Drosophilidae	Drosophilinae	C
50290	Drosophila melanogaster	7227	NM_001104116	NM_001104116.3_cds_NP_001097586.1_1	Drosophilidae	Drosophilinae	C
LOC6583183	Drosophila mojavensis	7230	NW_025318899.1	NW_025318899.1_cds_XP_002008859.1_3620	Drosophilidae	Drosophilinae	C
LOC132792566	Drosophila nasuta	42062	NC_083457.1	NC_083457.1_cds_XP_060657976.1_5750	Drosophilidae	Drosophilinae	C
LOC108651886	Drosophila navojoa	7232	NW_022045982.1	NW_022045982.1_cds_XP_017957304.1_13	Drosophilidae	Drosophilinae	C
LOC111076754	Drosophila obscura	7282	NW_024542769.1	NW_024542769.1_cds_XP_022226371.1_179	Drosophilidae	Drosophilinae	C
LOC6600482	Drosophila persimilis	7234	NW_020825336.1	NW_020825336.1_cds_XP_002025673.1_156	Drosophilidae	Drosophilinae	C
LOC4812122	Drosophila pseudoobscura	7237	NC_046683.1	NC_046683.1_cds_XP_001352791.2_9098	Drosophilidae	Drosophilinae	C
LOC120449979	Drosophila santomea	129105	NC_053018.2	NC_053018.2_cds_XP_039488622.1_2487	Drosophilidae	Drosophilinae	C
LOC110178951	Drosophila serrata	7274	NW_018366417.1	NW_018366417.1_cds_XP_020801911.1_214	Drosophilidae	Drosophilinae	C
LOC117895078	Drosophila subobscura	7241	NC_048532.1	NC_048532.1_cds_XP_034658358.1_1098	Drosophilidae	Drosophilinae	C
LOC133843618	Drosophila sulfurigaster albostrigata	89887	NC_084883.1	NC_084883.1_cds_XP_062133231.1_5928	Drosophilidae	Drosophilinae	C
LOC6645467	Drosophila willistoni	7260	NW_025814056.1	NW_025814056.1_cds_XP_002068102.1_551	Drosophilidae	Drosophilinae	C
LOC131436079	Malaya genurostris	325434	NC_080572.1	NC_080572.1_cds_XP_058460526.1_4332	Culicidae	Culicinae	B
LOC131436314	Malaya genurostris	325434	NC_080572.1	NC_080572.1_cds_XP_058460959.1_4330	Culicidae	Culicinae	A
LOC128735801	Sabethes cyaneus	53552	NC_071354.1	NC_071354.1_cds_XP_053686261.1_2994	Culicidae	Culicinae	A
LOC128738226	Sabethes cyaneus	53552	NC_071354.1	NC_071354.1_cds_XP_053689185.1_2993	Culicidae	Culicinae	B
LOC131690538	Topomyia yanbarensis	2498891	NC_080672.1	NC_080672.1_cds_XP_058832385.1_5074	Culicidae	Culicinae	A
LOC129768709	Toxorhynchites rutilus septentrionalis	329112	NC_073745.1	NC_073745.1_cds_XP_055626488.1_5181	Culicidae	Culicinae	B
LOC129768710	Toxorhynchites rutilus septentrionalis	329112	NC_073745.1	NC_073745.1_cds_XP_055626489.1_5180	Culicidae	Culicinae	A
LOC129744816	Uranotaenia lowii	190385	NC_073692.1	NC_073692.1_cds_XP_055593507.1_6878	Culicidae	Culicinae	A
LOC129748614	Uranotaenia lowii	190385	NC_073692.1	NC_073692.1_cds_XP_055599252.1_9407	Culicidae	Culicinae	A
LOC129724442	Wyeomyia smithii	174621	NC_073695.1	NC_073695.1_cds_XP_055535337.1_6339	Culicidae	Culicinae	B
LOC129724443	Wyeomyia smithii	174621	NC_073695.1	NC_073695.1_cds_XP_055535338.1_6336	Culicidae	Culicinae	A
LOC129724444	Wyeomyia smithii	174621	NC_073695.1	NC_073695.1_cds_XP_055535339.1_6337	Culicidae	Culicinae	A

844

845 **Supplementary Table 3. Results of dN/dS analysis in CODEML**

		outgroup	Vago1	Vago (Culicinae)	Vago (Anophelinae)				
model	likelihood	ω0	ω1	ω2	ω3	2Δℓ	pvalue	df	model description
M0	-7009,86928	0.12623							M0: null model assumes the same ω for all branches.
M1	-7004,40804	0.106562	0.174765			10,922466	0.0009500506	1	M1: foreground group is only Vago1
M2	-7002,76217	0.0853288	0.17507	0.120153		14,214216	0.0008192609	2	M2: 2 foreground groups Vago1 and Vago Culicinae and Anophelinae
M3	-7001,25308	0.0878059	0.175461	0.149161	0.0972423	17,232404	0.0006330647	3	M3: 3 foreground groups (Vago1, Vago Culicinae and Vago Anophelinae)
# alpha critical value = 3.841459									

846 **Supplementary Table 4. GO terms**

GO term	GO ID	Functional annotation
biosynthetic process	GO:0009058	metabolism
calcium ion transmembrane transport	GO:0070588	ion transport
carbohydrate metabolic process	GO:0005975	metabolism
cell adhesion	GO:0007155	
cellular oxidant detoxification	GO:0098869	response to oxidative stress
cytoskeleton organization	GO:0007010	
dephosphorylation	GO:0016311	protein phosphorylation
DNA duplex unwinding	GO:0032508	
DNA replication	GO:0006260	
electron transport chain	GO:0022900	
fatty acid biosynthetic process	GO:0006633	metabolism
fatty acid metabolic process	GO:0006631	metabolism
G protein-coupled receptor signaling pathway	GO:0007186	
GO:0055114 NONAME - redox processes	GO:0055114 NONAME	response to oxidative stress
lipid metabolic process	GO:0006629	metabolism
lipid transport	GO:0006869	transport
metabolic process	GO:0008152	metabolism
methylation	GO:0032259	
microtubule-based movement	GO:0007018	
monoatomic ion transport	GO:0006811	ion transport
negative regulation of endopeptidase activity	GO:0010951	
peptidyl-tyrosine dephosphorylation	GO:0035335	protein phosphorylation
peptidyl-tyrosine phosphorylation	GO:0018108	protein phosphorylation
phosphorylation	GO:0016310	protein phosphorylation
potassium ion transport	GO:0006813	ion transport
protein folding	GO:0006457	
protein glycosylation	GO:0006486	
protein phosphorylation	GO:0006468	protein phosphorylation

protein transport	GO:0015031	transport
proteolysis	GO:0006508	
proton motive force-driven ATP synthesis	GO:0015986	
proton transmembrane transport	GO:1902600	
response to oxidative stress	GO:0006979	response to oxidative stress
ribosome biogenesis	GO:0042254	translation
RNA processing	GO:0006396	translation
rRNA processing	GO:0006364	translation
translation	GO:0006412	translation
translational initiation	GO:0006413	translation
transmembrane transport	GO:0055085	transport
tRNA processing	GO:0008033	translation

Supplementary Table 5. Oligonucleotide sequences.

Oligo name	**Target gene**	**Application**	**Sequence (5'-3')**
VAGOsg_x1_30rev_F		sgRNA	GAAATTAATACGACTCACTATAGGTCGCGTCGTGACTTTCGCGCGTTTTAGAGCTAGAAAT
VAGOsg_x3_67rev_F		sgRNA	GAAATTAATACGACTCACTATAGGTATATTTGTGACAACACTCCGTTTTAGAGCTAGAAATAGC
VAGOsg_x2_6rev_F		sgRNA	GAAATTAATACGACTCACTATAGGTTGGATCGTAGCACTTCCCAGTTTTAGAGCTAGAAATAGC
Sequencing primer F		sequencing	AGTCGGCCATCTTAGG
VAGO_35HA_RT		repair template for gene editing	GCATCAATTTACACTTAGTTCTAGTGGAGCCTGCGGTGTTGTCACAAATATAAATGTGTACACGATGGAA
Genotyping primer F		PCR	TCCGGTATTATTGGCTTTGTGC
Genotyping primer R		PCR	ACTCACTTTTCCATCGTGTACAC
NS5F-VR-D1Thai	NS5 DENV1 KDH0026A	qPCR	GGAAGGAGAAGGACTCCACA
NS5R-VR-D1Thai	NS5 DENV1 KDH0026A	qPCR	ATCCTTGTATCCCATCCGGCT
DSQ1-VR	DENV1 KDH0026A	qPCR probe	5'-FAM-CTCAGAGACATATCAAAGATTCCAGGG-BHQ1-3'

ZIKV-Af-for	NS1 ZIKV African strain	qPCR	GTCGCTGTCCAACACAAG
ZIKV-Af-for	NS1 ZIKV African strain	qPCR	CACCAGTGTTCTCTTGCAGACAT
ZIKV-Af-probe	NS1 ZIKV African strain	qpCR probe	6FAM/AGCCTACCT/ZEN/TGACAAGCAATCAGACACTCAA/ 3'IABkFQ
gBlock Zika	ZIKV African strain	Standards for qPCR	GAGGCATCAATATCGGACATGGCTTCGGACAGTCGCTGTCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAGAGAACACTGGTGGATAGAGGTTGGGGAAATGGGTGTGGACT
RPS17-EC1-qPCRfor	AAEL004175	qPCR	AAGAAGTGGCCATCATTCCA
RPS17-EC1-qPCRrev	AAEL004175	qPCR	GGTCTCCGGGTCGACTTC
Vago1-EC1-qPCRfor	AAEL000200	qPCR	AAATCCATTCCTGGTGCTTG
Vago1-EC1-qPCRrev	AAEL000200	qPCR	AACACTCCGGGTAATCCTTG
T7-VAGO2-EC-for	AAEL000165	dsRNA synthesis	GCCCGACGCgatcaagccggcaatATGAG
T7-VAGO2-EC-rev	AAEL000165	dsRNA synthesis	CGCCTCGGCTGGATTGAGAAATCCGTTCC
Vago2 EC2 for	AAEL000165	qPCR	gatcaagccggcaatATGAG
Vago2 EC2 rev	AAEL000165	qPCR	AGCATTCACCGGGAAAATC
T7-tag for		dsRNA synthesis	taatacgactcactatagggGCCCGACGC
T7-tag rev		dsRNA synthesis	taatacgactcactatagggCGCCTCGGC

849

850 **Supplementary Table 6: Hits for transcription factor DNA binding motifs from**
851 **HOCOMOCO H12CORE in the promoter of *VLG-1.*** Start and end positions of motifs are
852 indicated relative to *VLG-1* transcription start site.

TF	Start	End	Strand	TF Family	p-value	Corrected p-value
ZBTB49	-498	-476	-	More than 3 adjacent zinc fingers	3.311e-5	0.04778
CREM	-481	-464	+	CREB-related	1.312e-5	0.01893
ZNF766	-476	-454	-	More than 3 adjacent zinc fingers	1.718e-5	0.02479
MEF2B	-467	-454	+	Regulators of differentiation	1.841e-5	0.02657
ZNF615	-439	-420	-	More than 3 adjacent zinc fingers	1.510e-5	0.02179
ZNF26	-428	-406	-	More than 3 adjacent zinc fingers	2.999e-5	0.04328
FOXP3	-396	-387	-	FOX	2.624e-5	0.03786
NPAS2	-389	-370	+	PAS	2.636e-5	0.03804
IRX1	-381	-373	-	TALE-type HD	2.089e-5	0.03014
CLOCK	-380	-370	-	PAS	2.489e-5	0.03592
NPAS2	-380	-370	+	PAS	2.636e-5	0.03804
PGR	-353	-339	+	Steroid hormone receptors	2.037e-5	0.02939
ZIK1	-351	-329	-	More than 3 adjacent zinc fingers	3.155e-5	0.04553
ZNF613	-350	-326	+	More than 3 adjacent zinc fingers	2.812e-6	0.00406
ZNF570	-348	-330	-	More than 3 adjacent zinc fingers	1.268e-6	0.00183
ZNF362	-348	-326	-	More than 3 adjacent zinc fingers	1.589e-5	0.02293
LEF1	-345	-331	+	TCF7-related	1.274e-5	0.01838
ZNF791	-345	-323	+	More than 3 adjacent zinc fingers	2.317e-5	0.03343
SOX17	-344	-330	+	SOX-related	5.754e-6	0.00830
ZNF362	-343	-321	-	More than 3 adjacent zinc fingers	1.995e-5	0.02879
ZNF585A	-343	-321	-	More than 3 adjacent zinc fingers	2.291e-5	0.03306
ZNF716	-342	-318	-	More than 3 adjacent zinc fingers	2.612e-5	0.03769
ZNF354A	-334	-312	+	More than 3 adjacent zinc fingers	1.352e-5	0.01951
ONECUT2	-286	-265	-	HD-CUT	2.163e-5	0.03121
MEIS1	-286	-274	-	TALE-type HD	2.410e-5	0.03478
ZNF432	-269	-247	+	More than 3 adjacent zinc fingers	3.013e-6	0.00435
POU2F2	-230	-218	-	POU	9.311e-7	0.00134
POU5F1B	-230	-214	+	POU	2.084e-6	0.00301
VENTX	-230	-213	-	NK-related	2.118e-5	0.03056
ZNF768	-212	-190	+	More than 3 adjacent zinc fingers	4.853e-6	0.00700
ZNF490	-206	-184	-	More than 3 adjacent zinc fingers	2.443e-6	0.00353
LEF1	-177	-163	+	TCF7-related	5.689e-6	0.00821
TCF7L2	-176	-165	+	TCF7-related	1.161e-6	0.00168
TCF7	-176	-162	-	TCF7-related	1.945e-6	0.00281
TCF7L1	-176	-165	+	TCF7-related	2.296e-6	0.00331
LEF1	-176	-165	+	TCF7-related	2.158e-5	0.03114
YY2	-148	-135	-	More than 3 adjacent zinc fingers	4.667e-6	0.00673
YY1	-147	-136	-	More than 3 adjacent zinc fingers	2.094e-5	0.03022
NFIB	-133	-125	+	NF-1	3.027e-5	0.04368
THRB	-122	-101	+	Thyroid hormone receptor-related	2.203e-5	0.03179

ZNF558	-114	-90	+	More than 3 adjacent zinc fingers	2.692e-5	0.03885
NR2C2	-111	-100	+	RXR-related receptors	1.786e-5	0.02577
NR4A2	-111	-102	+	NGFI (NR4A)	2.051e-5	0.02960
NR2F2	-111	-100	+	RXR-related receptors	2.767e-5	0.03993
NR2F6	-110	-95	+	RXR-related receptors	1.368e-5	0.01974
NR2C1	-110	-95	+	RXR-related receptors	1.452e-5	0.02095
RARA	-110	-100	+	Thyroid hormone receptor-related	2.729e-5	0.03938
NR2C1	-110	-99	+	RXR-related receptors	3.342e-5	0.04823
TWIST1	-99	-84	-	Tal-related	5.000e-6	0.00722
MSC	-98	-87	-	Tal-related	2.312e-5	0.03336
TWIST2	-96	-87	+	Tal-related	5.224e-6	0.00754
ZBTB18	-96	-86	+	More than 3 adjacent zinc fingers	3.334e-5	0.04811
ZNF534	-83	-53	-	More than 3 adjacent zinc fingers	6.887e-6	0.00994
ZNF534	-82	-65	-	More than 3 adjacent zinc fingers	1.368e-5	0.01974
TFCP2L1	-71	-52	+	CP2-related	2.716e-5	0.03919
TFCP2L1	-60	-52	-	CP2-related	2.472e-5	0.03567
FOXB1	-53	-35	+	FOX	9.661e-6	0.01394
FOXC1	-53	-35	+	FOX	1.466e-5	0.02115
FOXA1	-50	-35	+	FOX	1.589e-5	0.02293
FOXA3	-49	-38	+	FOX	2.032e-5	0.02932
FOXA2	-47	-36	+	FOX	1.449e-5	0.02091
POU2F1	-47	-37	-	POU	1.538e-5	0.02219
POU5F1	-47	-37	-	POU	1.563e-5	0.02255
FOXA1	-47	-37	+	FOX	1.849e-5	0.02668
POU2F2	-47	-37	-	POU	2.228e-5	0.03215
FOXM1	-47	-36	+	FOX	2.710e-5	0.03911
ZSCAN1	-37	-20	-	Other with up to three adjacent zinc fingers	3.281e-5	0.04734
ZNF490	-20	2	-	More than 3 adjacent zinc fingers	8.147e-6	0.01176
GRHL2	-15	-5	-	Grainyhead-related	9.661e-6	0.01394
SMAD2	-7	2	+	SMAD	2.432e-5	0.03509
SMAD3	-6	2	-	SMAD	2.858e-5	0.04124
ZNF787	-2	13	+	Multiple dispersed zinc fingers	2.056e-5	0.02967
ZNF354A	-2	20	+	More than 3 adjacent zinc fingers	2.228e-5	0.03215
NRF1	25	40	-	NRF	1.466e-5	0.02115
NPAS4	39	49	-	PAS	1.067e-6	0.00154

853

854 **REFERENCES**

855 1. Pierson, T.C. and M.S. Diamond, *The continued threat of emerging flaviviruses.* Nat
856 Microbiol, 2020. **5**(6): p. 796-812.
857 2. World Health Organization. *Dengue: Guidelines for Diagnosis, Treatment, Prevention*
858 *and Control: New Edition* (2009).
859 3. Brady, O.J., et al., *Refining the global spatial limits of dengue virus transmission by*
860 *evidence-based consensus.* PLoS Negl Trop Dis, 2012. **6**(8): p. e1760.
861 4. Bhatt, S., et al., *The global distribution and burden of dengue.* Nature, 2013. **496**(7446):
862 p. 504-7.
863 5. Musso, D., A.I. Ko, and D. Baud, *Zika Virus Infection - After the Pandemic.* N Engl J Med,
864 2019. **381**(15): p. 1444-1457.
865 6. Kraemer, M.U., et al., *The global distribution of the arbovirus vectors Aedes aegypti and*
866 *Ae. albopictus.* Elife, 2015. **4**: p. e08347.
867 7. Kraemer, M.U.G., et al., *Past and future spread of the arbovirus vectors Aedes aegypti*
868 *and Aedes albopictus.* Nat Microbiol, 2019. **4**(5): p. 854-863.
869 8. Flores, H.A. and S.L. O'Neill, *Controlling vector-borne diseases by releasing modified*
870 *mosquitoes.* Nat Rev Microbiol, 2018. **16**(8): p. 508-518.
871 9. Kean, J., et al., *Fighting Arbovirus Transmission: Natural and Engineered Control of*
872 *Vector Competence in Aedes Mosquitoes.* Insects, 2015. **6**(1): p. 236-78.
873 10. Sigle, L.T. and E.A. McGraw, *Expanding the canon: Non-classical mosquito genes at the*
874 *interface of arboviral infection.* Insect Biochem Mol Biol, 2019. **109**: p. 72-80.
875 11. Gubler, D.J., et al., *Variation in susceptibility to oral infection with dengue viruses*
876 *among geographic strains of Aedes aegypti.* Am J Trop Med Hyg, 1979. **28**(6): p. 1045-
877 52.
878 12. Salazar, M.I., et al., *Dengue virus type 2: replication and tropisms in orally infected*
879 *Aedes aegypti mosquitoes.* BMC Microbiol, 2007. **7**: p. 9.
880 13. Franz, A.W., et al., *Tissue Barriers to Arbovirus Infection in Mosquitoes.* Viruses, 2015.
881 **7**(7): p. 3741-67.
882 14. Hall, D.R., et al., *Mosquito immune cells enhance dengue and Zika virus dissemination*
883 *in Aedes aegypti.* bioRxiv, 2024.
884 15. Leite, T., et al., *Distinct Roles of Hemocytes at Different Stages of Infection by Dengue*
885 *and Zika Viruses in Aedes aegypti Mosquitoes.* Front Immunol, 2021. **12**: p. 660873.
886 16. Raquin, V. and L. Lambrechts, *Dengue virus replicates and accumulates in Aedes aegypti*
887 *salivary glands.* Virology, 2017. **507**: p. 75-81.
888 17. Bronkhorst, A.W. and R.P. van Rij, *The long and short of antiviral defense: small RNA-*
889 *based immunity in insects.* Curr Opin Virol, 2014. **7**: p. 19-28.
890 18. Mongelli, V. and M.C. Saleh, *Bugs Are Not to Be Silenced: Small RNA Pathways and*
891 *Antiviral Responses in Insects.* Annu Rev Virol, 2016. **3**(1): p. 573-589.
892 19. Suzuki, Y., et al., *Non-retroviral Endogenous Viral Element Limits Cognate Virus*
893 *Replication in Aedes aegypti Ovaries.* Curr Biol, 2020. **30**(18): p. 3495-3506 e6.
894 20. Rosendo Machado, S., T. van der Most, and P. Miesen, *Genetic determinants of antiviral*
895 *immunity in dipteran insects - Compiling the experimental evidence.* Dev Comp
896 Immunol, 2021. **119**: p. 104010.
897 21. Merkling, S.H. and R.P. van Rij, *Beyond RNAi: antiviral defense strategies in Drosophila*
898 *and mosquito.* J Insect Physiol, 2013. **59**(2): p. 159-70.
899 22. Sim, S., N. Jupatanakul, and G. Dimopoulos, *Mosquito immunity against arboviruses.*
900 Viruses, 2014. **6**(11): p. 4479-504.

23. Alonso-Palomares, L.A., et al., *Molecular Basis for Arbovirus Transmission by Aedes aegypti Mosquitoes.* Intervirology, 2018. **61**(6): p. 255-264.
24. Dostert, C., et al., *The Jak-STAT signaling pathway is required but not sufficient for the antiviral response of drosophila.* Nat Immunol, 2005. **6**(9): p. 946-53.
25. Deddouche, S., et al., *The DExD/H-box helicase Dicer-2 mediates the induction of antiviral activity in drosophila.* Nat Immunol, 2008. **9**(12): p. 1425-32.
26. Paradkar, P.N., et al., *Secreted Vago restricts West Nile virus infection in Culex mosquito cells by activating the Jak-STAT pathway.* Proc Natl Acad Sci U S A, 2012. **109**(46): p. 18915-20.
27. Paradkar, P.N., et al., *Dicer-2-dependent activation of Culex Vago occurs via the TRAF-Rel2 signaling pathway.* PLoS Negl Trop Dis, 2014. **8**(4): p. e2823.
28. Asad, S., R. Parry, and S. Asgari, *Upregulation of Aedes aegypti Vago1 by Wolbachia and its effect on dengue virus replication.* Insect Biochem Mol Biol, 2018. **92**: p. 45-52.
29. Labropoulou, V., et al., *Single domain von Willebrand factor type C "cytokines" and the regulation of the stress/immune response in insects.* Arch Insect Biochem Physiol, 2024. **115**(1): p. e22071.
30. Ruckert, C., et al., *Antiviral responses of arthropod vectors: an update on recent advances.* Virusdisease, 2014. **25**(3): p. 249-60.
31. Wang, H., G. Smagghe, and I. Meeus, *The Single von Willebrand factor C-domain protein (SVC) coding gene is not involved in the hymenoptaecin upregulation after Israeli acute paralysis virus (IAPV) injection in the bumblebee Bombus terrestris.* Dev Comp Immunol, 2018. **81**: p. 152-155.
32. Niu, J., I. Meeus, and G. Smagghe, *Differential expression pattern of Vago in bumblebee (Bombus terrestris), induced by virulent and avirulent virus infections.* Sci Rep, 2016. **6**: p. 34200.
33. Wang, H., G. Smagghe, and I. Meeus, *The role of a single gene encoding the Single von Willebrand factor C-domain protein (SVC) in bumblebee immunity extends beyond antiviral defense.* Insect Biochem Mol Biol, 2017. **91**: p. 10-20.
34. Gao, J., et al., *Interferon functional analog activates antiviral Jak/Stat signaling through integrin in an arthropod.* Cell Rep, 2021. **36**(13): p. 109761.
35. Li, C., et al., *Activation of Vago by interferon regulatory factor (IRF) suggests an interferon system-like antiviral mechanism in shrimp.* Sci Rep, 2015. **5**: p. 15078.
36. Hixson, B., et al., *A transcriptomic atlas of Aedes aegypti reveals detailed functional organization of major body parts and gut regional specializations in sugar-fed and blood-fed adult females.* Elife, 2022. **11**.
37. Lykke-Andersen, S. and T.H. Jensen, *Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes.* Nat Rev Mol Cell Biol, 2015. **16**(11): p. 665-77.
38. Gloria-Soria, A., D.E. Brackney, and P.M. Armstrong, *Saliva collection via capillary method may underestimate arboviral transmission by mosquitoes.* Parasit Vectors, 2022. **15**(1): p. 103.
39. Foo, J., et al., *Mitochondria-mediated oxidative stress during viral infection.* Trends Microbiol, 2022. **30**(7): p. 679-692.
40. Zhang, Z., L. Rong, and Y.P. Li, *Flaviviridae Viruses and Oxidative Stress: Implications for Viral Pathogenesis.* Oxid Med Cell Longev, 2019. **2019**: p. 1409582.
41. Gullberg, R.C., et al., *Oxidative stress influences positive strand RNA virus genome synthesis and capping.* Virology, 2015. **475**: p. 219-29.

947 42. Camini, F.C., et al., *Implications of oxidative stress on viral pathogenesis.* Arch Virol,
948 2017. **162**(4): p. 907-917.
949 43. Olagnier, D., et al., *Cellular oxidative stress response controls the antiviral and apoptotic*
950 *programs in dengue virus-infected dendritic cells.* PLoS Pathog, 2014. **10**(12): p.
951 e1004566.
952 44. Oliveira, J.H.M., et al., *Catalase protects Aedes aegypti from oxidative stress and*
953 *increases midgut infection prevalence of Dengue but not Zika.* PLoS Negl Trop Dis, 2017.
954 **11**(4): p. e0005525.
955 45. Talyuli, O.A.C., et al., *The Aedes aegypti peritrophic matrix controls arbovirus vector*
956 *competence through HPx1, a heme-induced peroxidase.* PLoS Pathog, 2023. **19**(2): p.
957 e1011149.
958 46. Estevez-Castro, C.F., et al., *Neofunctionalization driven by positive selection led to the*
959 *retention of the loqs2 gene encoding an Aedes specific dsRNA binding protein.* BMC
960 Biol, 2024. **22**(1): p. 14.
961 47. David, K.T., J.R. Oaks, and K.M. Halanych, *Patterns of gene evolution following*
962 *duplications and speciations in vertebrates.* PeerJ, 2020. **8**: p. e8813.
963 48. Birchler, J.A. and H. Yang, *The multiple fates of gene duplications: Deletion,*
964 *hypofunctionalization, subfunctionalization, neofunctionalization, dosage balance*
965 *constraints, and neutral variation.* Plant Cell, 2022. **34**(7): p. 2466-2474.
966 49. Shaw, W.R. and F. Catteruccia, *Vector biology meets disease control: using basic*
967 *research to fight vector-borne diseases.* Nat Microbiol, 2019. **4**(1): p. 20-34.
968 50. Jumper, J., et al., *Highly accurate protein structure prediction with AlphaFold.* Nature,
969 2021. **596**(7873): p. 583-589.
970 51. Varadi, M., et al., *AlphaFold Protein Structure Database: massively expanding the*
971 *structural coverage of protein-sequence space with high-accuracy models.* Nucleic
972 Acids Res, 2022. **50**(D1): p. D439-D444.
973 52. Fansiri, T., et al., *Genetic mapping of specific interactions between Aedes aegypti*
974 *mosquitoes and dengue viruses.* PLoS Genet, 2013. **9**(8): p. e1003621.
975 53. Aubry, F., et al., *Recent African strains of Zika virus display higher transmissibility and*
976 *fetal pathogenicity than Asian strains.* Nat Commun, 2021. **12**(1): p. 916.
977 54. Fontaine, A., et al., *Excretion of dengue virus RNA by Aedes aegypti allows non-*
978 *destructive monitoring of viral dissemination in individual mosquitoes.* Sci Rep, 2016.
979 **6**: p. 24885.
980 55. Lequime, S., et al., *Genetic Drift, Purifying Selection and Vector Genotype Shape Dengue*
981 *Virus Intra-host Genetic Diversity in Mosquitoes.* PLoS Genet, 2016. **12**(6): p. e1006111.
982 56. Kistler, K.E., L.B. Vosshall, and B.J. Matthews, *Genome engineering with CRISPR-Cas9 in*
983 *the mosquito Aedes aegypti.* Cell Rep, 2015. **11**(1): p. 51-60.
984 57. Concordet, J.P. and M. Haeussler, *CRISPOR: intuitive guide selection for CRISPR/Cas9*
985 *genome editing experiments and screens.* Nucleic Acids Res, 2018. **46**(W1): p. W242-
986 W245.
987 58. Jasinskiene, N., J. Juhn, and A.A. James, *Microinjection of A. aegypti embryos to obtain*
988 *transgenic mosquitoes.* J Vis Exp, 2007(5): p. 219.
989 59. Ranwez, V., et al., *MACSE v2: Toolkit for the Alignment of Coding Sequences Accounting*
990 *for Frameshifts and Stop Codons.* Mol Biol Evol, 2018. **35**(10): p. 2582-2584.
991 60. Minh, B.Q., et al., *IQ-TREE 2: New Models and Efficient Methods for Phylogenetic*
992 *Inference in the Genomic Era.* Mol Biol Evol, 2020. **37**(5): p. 1530-1534.

61. Letunic, I. and P. Bork, *Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree display and annotation.* Nucleic Acids Res, 2021. **49**(W1): p. W293-W296.
62. Yang, Z., *PAML 4: phylogenetic analysis by maximum likelihood.* Mol Biol Evol, 2007. **24**(8): p. 1586-91.
63. Alvarez-Carretero, S., P. Kapli, and Z. Yang, *Beginner's Guide on the Use of PAML to Detect Positive Selection.* Mol Biol Evol, 2023. **40**(4).
64. Yang, Z. and R. Nielsen, *Synonymous and nonsynonymous rate variation in nuclear genes of mammals.* J Mol Evol, 1998. **46**(4): p. 409-18.
65. Yang, Z., *On the best evolutionary rate for phylogenetic analysis.* Syst Biol, 1998. **47**(1): p. 125-33.
66. Raquin, V., et al., *Individual co-variation between viral RNA load and gene expression reveals novel host factors during early dengue virus infection of the Aedes aegypti midgut.* PLoS Negl Trop Dis, 2017. **11**(12): p. e0006152.
67. Martin, M., *Cutadapt removes adapter sequences from high-throughput sequencing reads.* 2011, 2011. **17**(1): p. 3.
68. Patro, R., et al., *Salmon provides fast and bias-aware quantification of transcript expression.* Nat Methods, 2017. **14**(4): p. 417-419.
69. Dobin, A., et al., *STAR: ultrafast universal RNA-seq aligner.* Bioinformatics, 2013. **29**(1): p. 15-21.
70. Liao, Y., G.K. Smyth, and W. Shi, *featureCounts: an efficient general purpose program for assigning sequence reads to genomic features.* Bioinformatics, 2013. **30**(7): p. 923-930.
71. Team, R.C., *R: A language and environment for statistical computing.* MSOR connections, 2014. **1**.
72. Soneson, C., M.I. Love, and M.D. Robinson, *Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences.* F1000Research, 2015. **4**.
73. Love, M.I., W. Huber, and S. Anders, *Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.* Genome Biol, 2014. **15**(12): p. 550.
74. Benjamini, Y. and Y. Hochberg, *Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing.* Journal of the Royal Statistical Society: Series B (Methodological), 2018. **57**(1): p. 289-300.
75. Gene Ontology, C., et al., *The Gene Ontology knowledgebase in 2023.* Genetics, 2023. **224**(1).
76. Dickson, L.B., et al., *Exome-wide association study reveals largely distinct gene sets underlying specific resistance to dengue virus types 1 and 3 in Aedes aegypti.* PLoS Genet, 2020. **16**(5): p. e1008794.
77. Vorontsov, I.E., et al., *HOCOMOCO in 2024: a rebuild of the curated collection of binding models for human and mouse transcription factors.* Nucleic Acids Res, 2024. **52**(D1): p. D154-D163.
78. Barrett, T., et al., *NCBI GEO: archive for functional genomics data sets--update.* Nucleic Acids Res, 2013. **41**(Database issue): p. D991-5.

Figure 1.

A



B



C

D AaeVLG-1 3D structure



Figure 2.


A
Midgut
B
Carcass
C
Head
D
Midgut
E
Carcass
F
Head
VLG-1
VLG-2
log10 expression
Day:
0
2
7
9
Starved
Mock bloodmeal
DENV-negative
DENV-positive
DENV bloodmeal

Figure 3.


A
VLG-1Δ (AAEL000200) mutant construct:
Wild-type control:
5'
sgRNA1
ATG
exon 1
sgRNA2
exon 2
sgRNA3
stop
exon 3
3'
35 bp
35 bp
repair template
246-bp deletion
+
34-bp insertion
Gene editing in VLG-1Δ mutant:
ATG
exon 1
ex.2
34-bp insertion
stop
ex.3
1
74
246
492
523
position (nt)
246
492
523
ATCACCCTGGGCATCAATTTACATCAATTTACACTTAGTTCTAGTGGAGCCTGCGGTGTTGTCACAAATATAAATGTGTACACGATGGAAAAGTGAGTTATCATTAA
B
1
19
35
103
(aa)
Wild-type control
5'
Signal peptide
Single Von Willebrand type C domain
3'
113 aa
VLG-1Δ mutant
5'
Signal peptide
3'
58 aa
Mutated domain
C
Males
Survival (%)
100
50
0
***
0
20
40
60
Time (days)
D
Females
Survival (%)
100
50
0
*
0
20
40
60
Time (days)
Control line
VLG-1Δ mutants
E
Fecundity
Egg count per female
150
100
50
0
ns
Control
VLG-1Δ
F
Fertility
Viable larvae/eggs laid (%)
100
50
0
ns
Control
VLG-1Δ
Control line
VLG-1Δ mutants

Figure 4.


A
Midgut infection
B
Carcass dissemination
C
Carcass-to-head dissemination
DENV-1 prevalence (%)
Days post bloodmeal :
nd
Control line
VLG-1Δ mutants
Exp. #1
Exp. #2
D
Midgut
E
Carcass
F
Head
DENV-1 viral RNA (log10 copies/tissue)
G
Transmission efficiency
ns
DENV-1-positive saliva (%)

Figure 5.


A
Midgut infection
B
Carcass dissemination
C
Carcass-to-head dissemination
ZIKV prevalence (%)
100
80
60
40
20
0
****
Days post bloodmeal :
2
5
9
Control line
VLG-1Δ mutants
D
Midgut
E
Carcass
F
Head
ZIKV viral RNA (log10 copies/tissue)
10^12
10^10
10^8
10^6
10^4
****
****
**
**
*
G
Transmission efficiency
ZIKV-positive saliva (%)
100
50
0
ns
ns
ns
7
10
14

Figure 6.


A
Midgut
Mock
DENV
Number of differentially expressed genes
UP
DOWN
Day:
B
Body
C
Day 2 up
Body - DENV
Body - mock
Midgut - DENV
Midgut - mock
D
Day 2 down
Midgut- mock
E
Day 2
Day 5
Day 9
Fold Enrichment
FDR
0.0001
0.001
0.01
0.05
Comparison
VLG-1Δ mock vs Control mock
VLG-1Δ DENV vs Control DENV
translation
protein phosphorylation
metabolism
response to oxidative stress
ion transport
transport

Figure S1.

A Phylogeny of *Vago*-like genes in Diptera



Figure S2.


A
VLG-1 expression (log10)
10 1
10 0
10-1
10-2
10-3
10-4
10-5
****
Control line
VLG-1Δ mutant
B
Coverage of VLG-1 (AAEL000200) (reads/nucleotide)
VLG-1Δ mock #1
VLG-1Δ mock #2
VLG-1Δ mock #3
Control mock #1
Control mock #2
Control mock #3
9000
6000
3000
0
0
200
400
600
Position (nt)
C
Control line
VLG-1Δmutants
15 kDa
anti-VLG-1 antibody
D
VLG-2 expression (log10)
10-1
10-2
10-3
10-4
ns
Control line
VLG-1Δ mutant


E
VLG-1 (AAEL000200)
VLG-2 (AAEL000165)
Mean normalized read counts
8000
6000
4000
2000
0
Day 2
Day 5
Day 9
Control line
VLG-1Δ mutants

Figure S3.


A
Prevalence in heads
DENV-1 positive heads (%)
100
80
60
40
20
0
***
****
*
B
Viral load in heads
DENV-1 viral RNA (log10 copies/head)
10^6
10^5
10^4
10^3
ns
Control + dsLuciferase
Control + dsAaeVLG-2
VLG-1Δ mutant + dsLuciferase
VLG-1Δ mutant + dsAaeVLG-2
C
AaeVLG-2 knockdown efficiency
Transcript RA
Expression level
0.25
0.20
0.15
0.10
0.05
0
****
****
D
AaeVLG-2 knockdown efficiency
Transcript RB
Expression level
0.5
0.4
0.3
0.2
0.1
0
****
****

Figure S4.


A
Day 5
UP
Body DENV
Body mock
Midgut DENV
Midgut mock
4
5
8
0
0
64
0
0
133
1
0
0
3
0
94
B
Day 5
DOWN
Body DENV
Body mock
Midgut DENV
Midgut mock
7
5
2
1
3
174
0
0
94
3
0
0
2
1
144
C
Day 9
UP
Body DENV
Body mock
Midgut DENV
Midgut mock
3
12
5
0
0
21
0
0
89
0
0
0
0
0
61
D
Day 9
DOWN
Body DENV
Body mock
Midgut DENV
Midgut mock
10
9
6
0
2
40
2
0
214
4
0
0
0
0
108

Figure S5.


A
Midgut
B
Body
C
D
E
F
Day 2
Day 5
Day 9
Differential expression
Up
No
Down
-log10 (p-adj.)
log2 Fold Change

Figure S6.


Family
Znf (others) (n = 14)
Hormone receptor−related (n = 3)
FOX (n = 2)
PAS (n = 2)
POU (n = 2)
TALE−type HD (n = 2)
TCF7−related (n = 2)
CP2−related (n = 1)
CREB−related (n = 1)
Grainyhead−related (n = 1)
HD−CUT (n = 1)
NF−1 (n = 1)
NGFI (NR4A) (n = 1)
NK−related (n = 1)
NRF (n = 1)
Regulators of differentiation (n = 1)
SMAD (n = 1)
SOX−related (n = 1)
Tal−related (n = 1)
VLG-1
−500
−450
−400
−350
−300
−250
−200
−150
−100
−50
TSS
+50
Nucleotide position